Chemical modification of small interfering RNA with minimal fluorine content

By fine-tuning the positions of 2'-O-methyl and 2'-F in RNA interference oligonucleotides to form specific modification patterns, the problems of oligonucleotide degradation and toxicity in vivo are solved, and RNAi activity and stability are improved pharmacodynamic properties are optimized.

CN114761557BActive Publication Date: 2024-11-15NOVO NORDISK AS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080082980.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-10-02
Filing Date
2020-10-02
Publication Date
2024-11-15
Estimated Expiration
2040-10-02

AI Technical Summary

Technical Problem

Existing RNA interferes with slow degradation of oligonucleotides in vivo, leading to potential toxicity, especially 2'-F modifications may cause reduced cellular proteins and DNA breakage, and improper 2'-O-methyl modifications can interfere with RNA protein binding and Inhibit RNAi activity, affecting stability and tolerance.

Method used

By fine-tuning the positions of 2'-O-methyl and 2'-F in RNA interference oligonucleotides, specific modification patterns are adopted, such as using 2'-F and 2 at specific positions of the sense and antisense strands. '-O-methyl modification, forming a tetracyclic or tricyclic structure, enhancing the stability and RNAi activity of the oligonucleotide.

Benefits of technology

Improves the potency and duration of oligonucleotides, reduces the content of 2'-F, enhances the tolerance of 2'-O-methyl, and optimizes the pharmacokinetic and pharmacodynamic properties of the RNAi platform. Reduces potential toxicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003669150660000281
    Figure BDA0003669150660000281
  • Figure BDA0003669150660000291
    Figure BDA0003669150660000291
  • Figure BDA0003669150660000301
    Figure BDA0003669150660000301
Patent Text Reader

Abstract

The present invention provides oligonucleotides for reducing the expression or activity of a gene, compositions thereof, and methods of use thereof, wherein the oligonucleotides contain 2'-O-methyl (2'-OMe) and 2'-deoxy-2'-fluoro (2'-F) modifications.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Related Applications

[0002] This application claims the benefit of U.S. Provisional Patent Application No. 62 / 909,278, filed on October 2, 2019, under 35 U.S.C. §119(e), the contents of which are incorporated herein by reference in their entirety. Technical Field

[0003] The present disclosure relates to oligonucleotides (eg, RNA interference oligonucleotides) comprising 2'-O-methyl (2'-OMe) and 2'-deoxy-2'-fluoro (2'-F) modifications. Background of the Invention

[0005] Oligonucleotides that reduce gene expression via RNA interference (RNAi) approaches have been developed. For example, RNAi oligonucleotides with a size of 19 to 25 nucleotides and at least one 3' overhang having 1 to 5 nucleotides have been developed for each chain (see, e.g., U.S. Patent No. 8,372,968). Longer oligonucleotides processed by Dicer to produce active RNAi products have also been developed (see, e.g., U.S. Patent No. 8,883,996). Further work has produced extended double-stranded oligonucleotides, wherein at least one end of at least one chain extends beyond the duplex targeting region, including structures in which one of the chains includes a thermodynamically stable tetracyclic structure (see, e.g., U.S. Patent Nos. 8,513,207 and 8,927,705 and WO2010033225, which are incorporated herein by reference in their entirety). Such structures may include single-stranded extensions (on one or both sides of the molecule) and double-stranded extensions.

[0006] Chemical modification of such RNAi oligonucleotides is necessary to fully exploit the therapeutic potential of such molecules. Various chemical modifications have been developed and applied to RNAi oligonucleotides to improve their pharmacokinetic and pharmacodynamic properties (Deleavey and Damha, CHEM. BIOL., 19: 937-954, 2012), and to block inherent immune activation (Judge et al., MOL. THER., 13: 494-505, 2006). One of the most common chemical modifications is the 2'-OH of the furanose of the ribonucleotide because it is involved in nuclease degradation. Fully chemically modified siRNAs with a combination of 2'-O-methyl (2'-OMe) and 2'-deoxy-2'-fluoro (2'-F) throughout the duplex have been reported and show excellent stability and RNAi activity (Morrissey et al., HEPATOLOGY, 41: 1349-1356, 2005; Allerson et al., J. MED. CHEM., 48: 901-904, 2005; Hassler et al., NUCLEIC ACID RES., 46: 2185-2196, 2018). Recently, N-acetylgalactosamine (GalNAc)-conjugated chemically modified siRNAs have demonstrated efficient asialoglycoprotein receptor (ASGPr)-mediated delivery to hepatocytes in vivo (Nair et al., J. AM. CHEM. SOC., 136: 16958-16961, 2014). Several GalNAc-conjugated RNAi platforms, including the GalNAc Dicer-substrate conjugate (GalXC) platform, have entered clinical development for the treatment of a wide range of human diseases.

[0007] A major problem in the development of oligonucleotide-based therapeutic agents (including RNAi GalNAc conjugates) using chemically modified nucleoside analogs is the potential toxicity associated with the modification. Therapeutic oligonucleotides can be slowly degraded in the patient's body, thereby releasing nucleoside analogs that can potentially be phosphorylated and incorporated into cell DNA or RNA. In the field of antiviral therapeutics, toxicity has been shown during the clinical development of many small molecule nucleotide inhibitors (Feng et al., ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60: 806-817, 2016). It is reported that the 2'-F modification of fully thiophosphorylated antisense oligonucleotides causes a reduction in cell protein and double-stranded DNA breaks, thereby producing acute hepatotoxicity in vivo (Shen et al., Nucleic Acid Res., 43: 4569-4578, 2015; Shen et al., NUCLEIC ACID RES., 46: 2204-2217, 2018). To date, no evidence has been observed regarding the liability of such 2'-F modifications in the context of RNAi oligonucleotides (Janas et al., NUCLEIC ACID THER., 26:363-371, 2016; Janas et al., NUCLEIC ACID THER., 27:11-22, 2016). In addition, 2'-F siRNAs are well tolerated in clinical trials. Nevertheless, there is still a need to minimize the use of non-natural nucleoside analogs (such as 2'-F modified nucleosides) in therapeutic RNA oligonucleotides.

[0008] Unlike 2'-deoxy-2'-fluoro RNA, 2'-O-methyl RNA is a naturally occurring RNA modification found in tRNA and other small RNAs in the form of post-transcriptional modifications. It is also known that the more bulky 2'-O-methyl modification confers better metabolic stability than the less bulky 2'-F modification. Therefore, 2'-OMe is superior to 2'-F in terms of stability and tolerance. However, it has been shown that if the more bulky 2'-Ome is not properly positioned in the sequence of the siRNA, it will interfere with RNA protein binding and inhibit RNAi activity (Chiu et al., RNA, 9: 1034-1048, 2003; Prakash et al., J.MED.CHEM., 48: 4247-4253, 2005; Zheng et al., FASEB J., 27: 4017-4026, 2013).

[0009] In order to further reduce the 2'-F content and increase the 2'-OMe content at the same time so that stability and tolerance can be improved without compromising RNAi activity, it is necessary to fine-tune the position (modification pattern) of 2'-OMe and 2'-F in DsiRNA conjugates that have already shown good efficacy and duration. The latest report has attempted to optimize the modification pattern of the 21 / 23-mer siRNA GalNAc conjugate platform (Foster et al., Mol. Ther. 26: 708-717, 2018). However, the report did not identify the pattern of 2'-OMe and 2'-F that conferred high efficacy and duration to oligonucleotides as disclosed herein, including positions with poor tolerance to 2'-OMe substitutions. The report also did not specifically identify advanced designs with minimal 2'-F content for the three-ring and four-ring GalXC platforms disclosed herein. Summary of the invention

[0010] The present disclosure is based on the study of strategies to modify oligonucleotides (eg, RNA interference oligonucleotides) with 2'-deoxy-2'-fluoro (2'-F) and 2'-O-methyl (2'-OMe) modifications to increase their potency and duration.

[0011] Thus, aspects of the present disclosure provide an oligonucleotide comprising: a sense strand comprising 17 to 36 nucleotides, wherein the sense strand has a first region (R1) and a second region (R2), wherein the second region of the sense strand comprises a first subregion (S1), a second subregion (S2), and a tetraloop (L) or a triloop (triL) joining the first region and the second region, wherein the first region and the second region form a second duplex (D2); an antisense strand comprising 20 to 22 nucleotides, wherein the antisense strand comprises at least one single-stranded nucleotide at its 3' end, wherein the sugar moiety of the nucleotide at position 5 of the antisense strand is modified with 2'-F and the sugar moiety of each of the remaining nucleotides of the antisense strand is modified with a modification selected from the group consisting of: Modifications: 2'-O-propargyl, 2'-O-propylamino, 2'-amino, 2'-ethyl, 2'-aminoethyl (EA), 2'-fluoro (2'-F), 2'-O-methyl (2'-OMe), 2'-O-methoxyethyl (2'-MOE), 2'-O-[2-(methylamino)-2-oxoethyl] (2'-O-NMA) and 2'-deoxy-2'-fluoro-β-d-arabinoic acid (2'-FANA), and wherein the sense strand and the antisense strand are separate strands; and a first duplex (D1) formed by the first region of the sense strand and the antisense strand, wherein the first duplex has a length of 12 to 20 base pairs and has 7 to 10 nucleotides modified with 2'-F at the 2'-position of the sugar portion.

[0012] The details of one or more embodiments of the present disclosure are set forth in the following description. Other features or advantages of the present disclosure will become apparent from the detailed description of several embodiments and the appended claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] Figures 1A to 1C Data from sense strand structure activity relationship (SAR) are shown. Knockdown of HAO1 target mRNA was measured 48 hours after transfection of different concentrations of nicked tetracyclic GalNAc conjugates in HAO1 stable cell line. Efficacy is expressed as half maximal inhibitory concentration (IC 50 )Sure. Figure 1A FIG. 5 is a graph showing the efficacy of the sense strand where positions 17 and 19 are modified with 2'-F. Figure 1B is a graph showing the efficacy of a sense strand wherein position 19 of the sense strand is modified with 2'-F and position 17 of the sense strand is modified with 2'-OMe. Figure 1C FIG. 5 is a graph showing the efficacy of the sense strand where positions 17 and 19 were modified with 2'-OMe.

[0014] FIG. 2A to FIG. 2D Data from the antisense structure activity relationship (SAR) are shown. Knockdown of HAO1 target mRNA was measured 48 hours after transfection of different concentrations of nicked tetracyclic GalNAc conjugates in HAO1 stable cell lines. Efficacy is expressed as half maximal inhibitory concentration (IC 50 )Sure. Figure 2A is a graph showing the efficacy of the antisense strand where positions 15, 17 and 19 are modified with 2'-F. Figure 2B is a graph showing the efficacy of the antisense strand, wherein positions 15 and 17 of the antisense strand are modified with 2'-F and position 19 of the antisense strand is modified with 2'-OMe. Figure 2C is a graph showing the efficacy of the antisense strand, wherein position 15 of the antisense strand is modified with 2'-F and positions 17 and 19 of the antisense strand are modified with 2'-OMe. Figure 2D is a graph showing the efficacy of the antisense strand, where positions 15, 17, and 19 were modified with 2'-OMe.

[0015] Figures 3A to 3H Data from the antisense structure activity relationship (SAR) are shown. Knockdown of HAO1 target mRNA was measured 48 hours after transfection of different concentrations of nicked tetracyclic GalNAc conjugates in HAO1 stable cell lines. Efficacy is expressed as half maximal inhibitory concentration (IC 50 )Sure. Figure 3Ais a graph showing the efficacy of the antisense strand, wherein positions 1 to 3 and 5 to 10 of the antisense strand are modified with 2'-F and position 4 of the antisense strand is modified with 2'-OMe. Figure 3B is a graph showing the efficacy of the antisense strand, wherein positions 1 to 3, 5 to 8, and 10 of the antisense strand are modified with 2'-F and positions 4 and 9 of the antisense strand are modified with 2'-OMe. Figure 3C is a graph showing the efficacy of the antisense strand, wherein positions 1 to 3, 5 to 6, 8 and 10 of the antisense strand are modified with 2'-F and positions 4, 7 and 9 of the antisense strand are modified with 2'-OMe. Figure 3D is a graph showing the efficacy of the antisense strand, wherein positions 1 to 3, 6, 8 and 10 of the antisense strand are modified with 2'-F and positions 4, 5, 7 and 9 of the antisense strand are modified with 2'-OMe. Figure 3E is a graph showing the efficacy of the antisense strand, wherein positions 1 to 2, 6, 8 and 10 of the antisense strand are modified with 2'-F and positions 3, 4, 5, 7 and 9 of the antisense strand are modified with 2'-OMe. Figure 3F is a graph showing the efficacy of the antisense strand, wherein positions 1 to 2, 8 and 10 of the antisense strand are modified with 2'-F and positions 3 to 7 and 9 of the antisense strand are modified with 2'-OMe. Figure 3G is a graph showing the efficacy of the antisense strand, wherein positions 1 to 2 of the antisense strand are modified with 2'-F and positions 3 to 9 of the antisense strand are modified with 2'-OMe. Figure 3H is a graph showing the efficacy of the antisense strand, wherein positions 1 to 2 of the antisense strand are modified with 2'-F and positions 3 to 10 of the antisense strand are modified with 2'-OMe.

[0016] FIG. 4A to FIG. 4E Data from the antisense strand structure activity relationship (SAR) are shown, in which the 2'-F modification at position 5 was maintained and positions 1 to 10 were probed with 2'-OMe. HAO1 target mRNA knockdown was measured 48 hours after transfection of different concentrations of nicked tetracyclic GalNAc conjugates in HAO1 stable cell lines. Efficacy is expressed as half maximal inhibitory concentration (IC 50 )Sure. Figure 4A is a graph showing the efficacy of the antisense strand wherein positions 1 to 3, 6, 8, 10, 14 and 15 of the antisense strand are modified with 2'-F and positions 4, 5, 7, 9 and 11 to 13 of the antisense strand are modified with 2'-OMe. Figure 4B is a graph showing the efficacy of the antisense strand wherein positions 1 to 3, 6, 8, 10 and 14 of the antisense strand are modified with 2'-F and positions 4, 5, 7, 9, 11 to 13 and 15 of the antisense strand are modified with 2'-OMe. Figure 4Cis a graph showing the efficacy of the antisense strand wherein positions 1, 2, 6, 8, 10, 14 and 15 of the antisense strand are modified with 2'-F and positions 3 to 5, 7, 9, 11 to 13 and 15 of the antisense strand are modified with 2'-OMe. Figure 4D is a graph showing the efficacy of the antisense strand wherein positions 2, 6, 8, 10, 14 and 15 of the antisense strand are modified with 2'-F and positions 1, 3 to 5, 7, 9 and 11 to 13 of the antisense strand are modified with 2'-OMe. Figure 4E is a graph showing the efficacy of the antisense strand, wherein positions 2 and 14 of the antisense strand are modified with 2'-F and positions 1, 3 to 13 and 15 of the antisense strand are modified with 2'-OMe.

[0017] Figures 5A to 5H Data from the antisense strand structure activity relationship (SAR) are shown, where 2'-F modifications at positions 2 and 14 are maintained while 2'-F additions are gradually made to the seed region at positions 3 to 6. HAO1 target mRNA knockdown was measured 48 hours after transfection of different concentrations of nicked tetracyclic GalNAc conjugates in HAO1 stable cell lines. Efficacy is expressed as half maximal inhibitory concentration (IC 50 )Sure. Figure 5A is a graph showing the efficacy of the antisense strand, wherein positions 2 and 14 of the antisense strand are modified with 2'-F and positions 1 and 3 to 13 of the antisense strand are modified with 2'-OMe. Figure 5B is a graph showing the efficacy of the antisense strand, wherein positions 2, 3, and 14 of the antisense strand are modified with 2'-F and positions 1 and 4 to 13 of the antisense strand are modified with 2'-OMe. Figure 5C is a graph showing the efficacy of the antisense strand, wherein positions 2, 4, and 14 of the antisense strand are modified with 2'-F and positions 1, 3, and 5 to 13 of the antisense strand are modified with 2'-OMe. Figure 5D is a graph showing the efficacy of the antisense strand, wherein positions 2, 5, and 14 of the antisense strand are modified with 2'-F and positions 1, 3, 4, and 6 to 13 of the antisense strand are modified with 2'-OMe. Figure 5E is a graph showing the efficacy of the antisense strand wherein positions 2, 6, and 14 of the antisense strand are modified with 2'-F and positions 1, 3 to 5 and 7 to 13 of the antisense strand are modified with 2'-OMe. Fig. 5F is a graph showing the efficacy of the antisense strand wherein positions 2, 3, 5 and 14 of the antisense strand are modified with 2'-F and positions 1, 4 and 6 to 13 of the antisense strand are modified with 2'-OMe. Figure 5G is a graph showing the efficacy of the antisense strand wherein positions 2, 5, 6 and 14 of the antisense strand are modified with 2'-F and positions 1, 3, 4 and 7 to 13 of the antisense strand are modified with 2'-OMe. Figure 5His a graph showing the efficacy of the antisense strand, wherein positions 2, 3, 5, 6, and 14 of the antisense strand are modified with 2'-F and positions 1, 4, and 7 to 13 of the antisense strand are modified with 2'-OMe.

[0018] 6A to 6F Data from the antisense strand structure activity relationship (SAR) are shown, where 2'-F modifications at positions 3 and 5 were maintained while 2'-F additions were gradually made to positions 7 to 10. HAO1 target mRNA knockdown was measured 48 hours after transfection of different concentrations of nicked tetracyclic GalNAc conjugates in HAO1 stable cell lines. Efficacy is expressed as half maximal inhibitory concentration (IC 50 )Sure. Fig. 6A is a graph showing the efficacy of the antisense strand, wherein positions 1, 2, 3, 5, and 14 of the antisense strand are modified with 2'-F. Figure 6B is a graph showing the efficacy of the antisense strand, wherein positions 1, 2, 3, 5, and 14 of the antisense strand are modified with 2'-F and position 9 of the sense strand is modified with 2'-OMe. Figure 6C is a graph showing the efficacy of the antisense strand, wherein positions 1, 2, 3, 5, 7, and 14 of the antisense strand are modified with 2'-F and position 9 of the sense strand is modified with 2'-OMe. Fig.6D is a graph showing the efficacy of the antisense strand, wherein positions 1, 2, 3, 5, 8, and 14 of the antisense strand are modified with 2'-F and position 9 of the sense strand is modified with 2'-OMe. Fig. 6E is a graph showing the efficacy of the antisense strand, wherein positions 1, 2, 3, 5, 9, and 14 of the antisense strand are modified with 2'-F and position 9 of the sense strand is modified with 2'-OMe. Fig. 6F is a graph showing the efficacy of the antisense strand, wherein positions 1, 2, 3, 5, 10, and 14 of the antisense strand are modified with 2'-F and position 9 of the sense strand is modified with 2'-OMe.

[0019] 7A to 7H Data from structure activity relationships (SAR) of the antisense strand with minimal 2'-F modifications are shown. Knockdown of HAO1 target mRNA was measured 48 hours after transfection of different concentrations of nicked tetracyclic GalNAc conjugates in HAO1 stable cell lines. Efficacy is expressed as half maximal inhibitory concentration (IC 50 )Sure. Fig. 7Ais a graph showing the efficacy of antisense and sense strands, wherein positions 1, 2, 3, 5, 7, 9, 11, 13 to 15, 17, and 19 of the antisense strand are modified with 2'-F and positions 4, 6, 8, 10, 12, 16, and 18 of the antisense strand are modified with 2'-OMe, and wherein positions 3, 5, 7 to 13, 15, 17, and 19 of the sense strand are modified with 2'-F and positions 1, 2, 4, 6, 14, 16, and 18 of the sense strand are modified with 2'-OMe. Figure 7B is a graph showing the efficacy of the antisense strand and the sense strand, wherein positions 2, 5, and 14 of the antisense strand are modified with 2'-F and positions 1, 3, 4, and 6 to 13 of the antisense strand are modified with 2'-OMe, wherein positions 8 to 11 of the sense strand are modified with 2'-F and positions 1 to 7 and 12 to 19 of the sense strand are modified with 2'-OMe. Figure 7C is a graph showing the efficacy of the antisense strand and the sense strand, wherein positions 1, 2, 5 and 14 of the antisense strand are modified with 2'-F and positions 3, 4 and 6 to 13 of the antisense strand are modified with 2'-OMe, wherein positions 8 to 11 of the sense strand are modified with 2'-F and positions 1 to 7 and 12 to 19 of the sense strand are modified with 2'-OMe. Fig.7D is a graph showing the efficacy of the antisense strand and the sense strand, wherein positions 1 to 3, 5, 7, and 14 of the antisense strand are modified with 2'-F and positions 4, 6, and 8 to 13 of the antisense strand are modified with 2'-OMe, wherein positions 8 to 11 of the sense strand are modified with 2'-F and positions 1 to 7 and 12 to 19 of the sense strand are modified with 2'-OMe. Fig. 7E is a graph showing the efficacy of the antisense strand and the sense strand, wherein positions 1 to 3, 5, 10 and 14 of the antisense strand are modified with 2'-F and positions 4, 6 to 9 and 11 to 13 of the antisense strand are modified with 2'-OMe, wherein positions 8 to 11 of the sense strand are modified with 2'-F and positions 1 to 7 and 12 to 19 of the sense strand are modified with 2'-OMe. Figure 7F is a graph showing the efficacy of the antisense strand and the sense strand, wherein positions 1 to 3, 5, 7, 9 and 14 of the antisense strand are modified with 2'-F and positions 4, 6, 8 and 10 to 13 of the antisense strand are modified with 2'-OMe, wherein positions 8 to 11 of the sense strand are modified with 2'-F and positions 1 to 7 and 12 to 19 of the sense strand are modified with 2'-OMe. Figure 7G is a graph showing the efficacy of the antisense strand and the sense strand, wherein positions 1 to 3, 5, 7, 10 and 14 of the antisense strand are modified with 2'-F and positions 4, 6, 8, 9 and 11 to 13 of the antisense strand are modified with 2'-OMe, wherein positions 8 to 11 of the sense strand are modified with 2'-F and positions 1 to 7 and 12 to 19 of the sense strand are modified with 2'-OMe. Figure 7His a graph showing the efficacy of the antisense strand and the sense strand, wherein positions 2, 3, 5, 7, 10 and 14 of the antisense strand are modified with 2'-F and positions 4, 6, 8, 9 and 11 to 13 of the antisense strand are modified with 2'-OMe, wherein positions 8 to 11 of the sense strand are modified with 2'-F and positions 1 to 7 and 12 to 19 of the sense strand are modified with 2'-OMe. Fig.7I To show that injection Figures 7A to 7H Figure 3. Graph of HAO1 mRNA expression in mice transfected with the oligonucleotides depicted in Figure 3.

[0020] Figure 8 is a graph showing HAO1 mRNA expression in mice injected with the oligonucleotides depicted in Table 8. Mice were injected with PBS as a control.

[0021] FIG. 9A to FIG. 9B In vitro and in vivo data are shown for a pool of oligonucleotides with minimal 2'-F modifications. Fig. 9A Graph showing APOC3 mRNA expression in cells transfected with the oligonucleotides depicted in Table 9. Fig. 9B is a graph showing APOC3 mRNA expression in mice injected with the oligonucleotides depicted in Table 9. Mice were injected with PBS as a control.

[0022] Fig.10 In vivo data are shown for GYS2 dsRNA with 3 GalNAc-conjugated nucleotides in the loop region and either a high 2'-F modification pattern or a low 2'-F modification pattern labeled pattern 1 or pattern 2. The antisense strand contained either 3 phosphorothioates (3PS) or 2 phosphorothioates (2PS) at the 5' end. DETAILED DESCRIPTION

[0023] Aspects of the present disclosure provide an oligonucleotide (e.g., an RNA interference oligonucleotide) comprising a modification pattern (e.g., 2'-deoxy-2'-fluoro (2'-F) and 2'-O-methyl (2'-OMe) modification pattern) that alters the activity of the oligonucleotide relative to its unmodified counterpart. Thus, the modification patterns provided herein may be useful for increasing the binding of an oligonucleotide to its target (also referred to as oligonucleotide efficacy) and / or reducing the binding of an oligonucleotide to a non-target (also referred to as an off-target effect). In some embodiments, the modification patterns provided herein may be useful for increasing the resistance of an oligonucleotide to degradation and / or increasing the duration of an oligonucleotide in a cell.

[0024] (I) Definition

[0025] Roughly: As used herein, when applied to one or more target values, the term "roughly" or "approximately" refers to a value similar to the stated reference value. In certain embodiments, unless otherwise stated or otherwise apparent from the context, the term "roughly" or "approximately" refers to a series of values ​​(unless such numbers will exceed 100% of the possible value) in either direction (greater than or less than) of 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less of the stated reference value.

[0026] Administration: As used herein, the term "administering" or "administering" means providing a substance (e.g., an oligonucleotide) to a subject in a pharmacologically applicable manner (e.g., to treat a condition of the subject). Oligonucleotides may also be administered by transfection or infection using methods known in the art, including but not limited to the methods described in McCaffrey et al. (2002), NATURE, 418(6893), 38-9 (hydrodynamic transfection) or Xia et al. (2002), NATURE BIOTECHNOL., 20(10), pp. 1006-10 (viral-mediated delivery).

[0027] Complementary: As used herein, the term "complementary" refers to a structural relationship between nucleotides (e.g., two nucleotides on opposite regions of a nucleic acid or a single nucleic acid strand) that allows the nucleotides to form base pairs with each other. For example, the purine nucleotides of a nucleic acid complementary to the pyrimidine nucleotides of the opposite nucleic acid can be base-paired together by forming hydrogen bonds with each other. In some embodiments, complementary nucleotides can be base-paired in a Watson-Crick manner or in any other manner that allows the formation of a stable duplex. In some embodiments, as described herein, two nucleic acids may have nucleotide sequences that are complementary to each other to form a complementary region.

[0028] Deoxyribonucleotide: As used herein, the term "deoxyribonucleotide" refers to a nucleotide having a hydrogen at the 2' position of its pentose sugar, as compared to a ribonucleotide. A modified deoxyribonucleotide is a deoxyribonucleotide having one or more modifications or atom substitutions other than at the 2' position, including modifications or substitutions in or of the sugar, phosphate group, or base.

[0029] Double-stranded oligonucleotide: As used herein, the term "double-stranded oligonucleotide" refers to an oligonucleotide that is substantially in the form of a duplex. In some embodiments, the complementary base pairing in the duplex region of a double-stranded oligonucleotide is formed between the antiparallel sequences of nucleotides with covalently separated nucleic acid chains. In some embodiments, the complementary base pairing in one or more duplex regions of a double-stranded oligonucleotide is formed between the antiparallel sequences of nucleotides with covalently attached nucleic acid chains. In some embodiments, the complementary base pairing in the duplex region of a double-stranded oligonucleotide is formed by folding (e.g., via a hairpin structure) to provide a single nucleic acid chain of complementary antiparallel sequences of nucleotides that base pair together. In some embodiments, a double-stranded oligonucleotide comprises two nucleic acid chains that are covalently separated from each other's fully duplexes. However, in some embodiments, a double-stranded oligonucleotide comprises two covalently separated nucleic acid chains of partial duplexes (e.g., having an overhang at one or both ends). In some embodiments, a double-stranded oligonucleotide comprises an antiparallel sequence of partially complementary nucleotides, and therefore may have one or more mispairings, which may include internal mispairings or end mispairings.

[0030] Duplex: As used herein, the term "duplex" with respect to a nucleic acid (eg, an oligonucleotide) refers to a structure formed by complementary base pairing of two antiparallel sequences of nucleotides.

[0031] Excipient: As used herein, the term "excipient" refers to a non-therapeutic agent that may be included in the composition, for example, to provide or contribute to a desired consistency or stabilizing effect.

[0032] Loop: As used herein, the term "loop" refers to an unpaired region of a nucleic acid (e.g., an oligonucleotide) flanked by two antiparallel regions of the nucleic acid that are sufficiently complementary to each other such that under appropriate hybridization conditions (e.g., in phosphate buffer, in cells), the two antiparallel regions flanking the unpaired region hybridize to form a duplex (referred to as the "stem").

[0033] Modified internucleotide linkages: As used herein, the term "modified internucleotide linkages" refers to internucleotide linkages having one or more chemical modifications compared to a reference internucleotide linkage comprising a phosphodiester bond. In some embodiments, the modified nucleotides are non-naturally occurring linkages. Typically, the modified internucleotide linkages impart one or more desired properties to the nucleic acid in which they are present. For example, modified nucleotides can improve thermal stability, resistance to degradation, nuclease resistance, solubility, bioavailability, biological activity, reduced immunogenicity, etc.

[0034] Modified nucleotides: As used herein, the term "modified nucleotides" refers to nucleotides having one or more chemical modifications compared to corresponding reference nucleotides, the corresponding reference nucleotides being selected from: adenine ribonucleotides, guanine ribonucleotides, cytosine ribonucleotides, uracil ribonucleotides, adenine deoxyribonucleotides, guanine deoxyribonucleotides, cytosine deoxyribonucleotides, and thymidine deoxyribonucleotides. In some embodiments, the modified nucleotides are non-naturally occurring nucleotides. In some embodiments, the modified nucleotides have one or more chemical modifications in their sugars, nucleobases, and / or phosphate groups. In some embodiments, the modified nucleotides have one or more chemical moieties conjugated to the corresponding reference nucleotides. Typically, the modified nucleotides impart one or more desired properties to the nucleic acid in which the modified nucleotides are present. For example, modified nucleotides can improve thermal stability, resistance to degradation, nuclease resistance, solubility, bioavailability, biological activity, reduced immunogenicity, and the like. In certain embodiments, the modified nucleotide comprises a 2'-O-methyl or 2'-F substitution at the 2' position of the ribose ring.

[0035] Nicked tetraloop structure: A "nicked tetraloop structure" is a structure of an RNAi oligonucleotide characterized by the presence of separate sense (passenger) and antisense (guide) strands, wherein the sense strand has a region complementary to the antisense strand such that the two strands form a duplex, and wherein at least one of the strands (usually the sense strand) extends from the duplex, wherein the extension contains a tetraloop and two self-complementary sequences that form a stem region adjacent to the tetraloop, wherein the tetraloop is constructed to stabilize an adjacent stem region formed by the self-complementary sequences of at least one strand.

[0036] Oligonucleotide: As used herein, the term "oligonucleotide" refers to a short nucleic acid, for example, less than 100 nucleotides in length. An oligonucleotide may comprise ribonucleotides, deoxyribonucleotides and / or modified nucleotides, including, for example, modified ribonucleotides. An oligonucleotide may be single-stranded or double-stranded. An oligonucleotide may or may not have a duplex region. As a collection of non-limiting examples, an oligonucleotide may be, but is not limited to, a small interfering RNA (siRNA), a microRNA (miRNA), a short hairpin RNA (shRNA), a Dicer substrate interfering RNA (dsiRNA), an antisense oligonucleotide, a short siRNA, or a single-stranded siRNA. In some embodiments, a double-stranded oligonucleotide is an RNAi oligonucleotide.

[0037] Overhang: As used herein, the term "overhang" refers to a terminal non-base paired nucleotide resulting from a strand or region extending beyond the end of a complementary strand with which the strand or region forms a duplex. In some embodiments, the overhang comprises one or more unpaired nucleotides extending from the duplex region at the 5' end or 3' end of a double-stranded oligonucleotide. In certain embodiments, the overhang is a 3' or 5' overhang on the antisense strand or sense strand of a double-stranded oligonucleotide.

[0038] Phosphate analogs: As used herein, the term "phosphate analogs" refers to chemical moieties that simulate the electrostatic and / or steric properties of a phosphate group. In some embodiments, the phosphate analog is positioned at the 5' terminal nucleotide of an oligonucleotide, rather than a 5' phosphate, which is generally susceptible to enzymatic removal. In some embodiments, the 5' phosphate analog contains phosphatase-resistant linkages. Examples of phosphate analogs include 5' phosphonates, such as 5' methylenephosphonates (5'-MP) and 5'-(E)-vinylphosphonates (5'-VP). In some embodiments, an oligonucleotide has a phosphate analog (referred to as a "4'-phosphate analog") at the 4'-carbon position of the sugar at the 5' terminal nucleotide. An example of a 4'-phosphate analog is an oxymethylphosphonate, in which the oxygen atom of the oxymethyl group is bound to a sugar moiety (e.g., at its 4'-carbon) or an analog thereof. See, e.g., International Patent Application PCT / US2017 / 049909 filed on September 1, 2017, U.S. Provisional Application No. 62 / 383,207 filed on September 2, 2016, and U.S. Provisional Application No. 62 / 393,401 filed on September 12, 2016, each of which is incorporated herein by reference for its content related to phosphate analogs. Other modifications of the 5' end of oligonucleotides have been developed (see, e.g., WO 2011 / 133871; U.S. Patent No. 8,927,513; and Prakash et al., (2015), NUCLEICACIDS RES., 43(6):2993-3011, each of which is incorporated herein by reference for its content related to phosphate analogs).

[0039] Reduced expression: As used herein, the term "reduced expression" of a gene refers to a reduction in the amount of an RNA transcript or protein encoded by a gene and / or a reduction in the amount of activity of a gene in a cell or subject compared to an appropriate reference cell or subject. For example, an operation of treating a cell with a double-stranded oligonucleotide (e.g., an oligonucleotide having an antisense strand complementary to a target mRNA sequence) may result in a reduction in the amount of RNA transcripts (e.g., encoded by a target gene), proteins, and / or enzymatic activity compared to cells not treated with double-stranded oligonucleotides. Similarly, "reduced expression" as used herein refers to an operation that causes a reduction in the expression of a gene (e.g., a target gene).

[0040] Complementary region: As used herein, the term "complementary region" refers to a nucleotide sequence of a nucleic acid (e.g., a double-stranded oligonucleotide) that is sufficiently complementary to an antiparallel sequence of nucleotides (e.g., a target nucleotide sequence within an mRNA) to allow hybridization between two sequences of nucleotides under appropriate hybridization conditions (e.g., in a phosphate buffer, in a cell, etc.). The complementary region may be completely complementary to a nucleotide sequence (e.g., a target nucleotide sequence present in an mRNA, or a portion thereof). For example, a complementary region that is completely complementary to a nucleotide sequence present in an mRNA has a continuous nucleotide sequence that is complementary to the corresponding sequence in the mRNA without any mismatches or gaps. Alternatively, a complementary region may be partially complementary to a nucleotide sequence (e.g., a nucleotide sequence present in an mRNA, or a portion thereof). For example, a complementary region that is partially complementary to a nucleotide sequence present in an mRNA has a continuous nucleotide sequence that is complementary to the corresponding sequence in the mRNA but contains one or more mismatches or gaps (e.g., 1, 2, 3 or more mismatches or gaps) compared to the corresponding sequence in the mRNA, with the proviso that the complementary region is still able to hybridize with the mRNA under appropriate hybridization conditions.

[0041] Ribonucleotide: As used herein, the term "ribonucleotide" refers to a nucleotide having ribose as its pentose containing a hydroxyl group at its 2' position. A modified ribonucleotide is a ribonucleotide having one or more modifications or atom substitutions other than at the 2' position, including modifications or substitutions in or of ribose, phosphate or base.

[0042] RNAi oligonucleotide: As used herein, the term "RNAi oligonucleotide" refers to (a) a double-stranded oligonucleotide having a sense strand (passenger) and an antisense strand (guide), wherein the antisense strand or a portion of the antisense strand is used by the Argonaute 2 (Ago2) endonuclease to cleave a target mRNA, or (b) a single-stranded oligonucleotide having a single antisense strand, wherein the antisense strand (or a portion of the antisense strand) is used by the Ago2 endonuclease to cleave a target mRNA.

[0043] Chain: As used herein, the term "chain" refers to a single contiguous sequence of nucleotides linked together via internucleotide linkages (eg, phosphodiester linkages, phosphorothioate linkages). In some embodiments, a chain has two free ends, eg, a 5'-end and a 3'-end.

[0044] Subject: As used herein, the term "subject" means any mammal, including mice, rabbits, and humans. In one embodiment, the subject is a human or non-human primate substrate. The term "individual" or "patient" can be used interchangeably with "subject".

[0045] Synthetic: As used herein, the term "synthetic" refers to nucleic acids or other molecules that are artificially synthesized (e.g., using a machine (e.g., a solid-state nucleic acid synthesizer)) or otherwise not derived from a natural source (e.g., a cell or organism) that normally produces the molecule.

[0046] Targeting ligand: As used herein, the term "targeting ligand" refers to a molecule (e.g., carbohydrate, amino sugar, cholesterol, polypeptide or lipid) that selectively binds to a homologous molecule (e.g., receptor) of a target tissue or cell and can be conjugated to another substance for the purpose of targeting another substance to a target tissue or cell. For example, in some embodiments, a targeting ligand can be conjugated to an oligonucleotide for the purpose of targeting an oligonucleotide to a specific tissue or cell of interest. In some embodiments, a targeting ligand selectively binds to a cell surface receptor. Therefore, in some embodiments, when conjugated to an oligonucleotide, a targeting ligand facilitates delivery of the oligonucleotide to a specific cell via selective binding to a receptor expressed on the cell surface and endosome internalization of a complex comprising an oligonucleotide, a targeting ligand and a receptor. In some embodiments, a targeting ligand is conjugated to an oligonucleotide via a linker that is cleaved after or during cellular internalization to release the oligonucleotide from the targeting ligand in the cell.

[0047] Tetraloop: As used herein, the term "tetraloop" refers to a loop that increases the stability of adjacent duplexes formed by hybridization of flanking sequences of nucleotides. The increase in stability can be detected as a melting temperature (T m ) is higher than the T of adjacent stem duplexes expected on average from a set of loops of comparable length consisting of randomly selected nucleotide sequences. m. For example, the tetraloop can confer a melting temperature of at least 50°C, at least 55°C, at least 56°C, at least 58°C, at least 60°C, at least 65°C, or at least 75°C to a hairpin comprising a duplex of at least 2 base pairs in length in 10 mM NaHPO4. In some embodiments, the tetraloop can stabilize base pairs in adjacent stem duplexes through stacking interactions. In addition, interactions between nucleotides in the tetraloop include, but are not limited to, non-Watson-Crick base pairing, stacking interactions, hydrogen bonding, and contact interactions (Cheong et al., NATURE 1990 August 16; 346(6285): 680-2; Heus and Pardi, SCIENCE 1991 July 12; 253(5016): 191-4). In some embodiments, the tetraloop comprises or consists of 3 to 6 nucleotides and is typically 4 to 5 nucleotides. In certain embodiments, the tetraloop comprises or consists of three, four, five or six nucleotides, which may be modified or unmodified (e.g., they may be conjugated or unconjugated to a targeting moiety). In one embodiment, the tetraloop consists of four nucleotides. Any nucleotide may be used in the tetraloop and the standard IUPAC-IUB symbols for such nucleotides may be used as described in Cornish-Bowden (1985) NUCL.ACIDS RES.13:3021-3030. For example, the letter "N" may be used to refer to any base that may be in the position, the letter "R" may be used to show A (adenine) or G (guanine) that may be in the position, and "B" may be used to show C (cytosine), G (guanine) or T (thymine) that may be in the position. Examples of tetraloops include the UNCG tetraloop family (e.g., UUCG), the GNRA tetraloop family (e.g., GAAA), and the CUUG tetraloop (Woese et al., PROC NATL ACAD SCI USA. 1990 November; 87(21):8467-71; Antao et al., NUCLEIC ACIDS RES. 1991 November 11; 19(21):5901-5). Examples of DNA tetraloops include the d(GNNA) tetraloop family (e.g., d(GTTA)), the d(GNRA) tetraloop family, the d(GNAB) tetraloop family, the d(CNNG) tetraloop family, and the d(TNCG) tetraloop family (e.g., d(TTCG)). See, e.g., Nakano et al., BIOCHEMISTRY, 41(48), 14281-292, 2002; Shinji et al., NIPPON KAGAKKAI KOEN YOKOSHU Vol. 78; No. 2; p. 731 (2000), which are incorporated herein by reference for their relevant disclosures. In some embodiments, the tetracyclic ring is contained within a nicked tetracyclic ring structure.

[0048] Treatment: As used herein, the term "treatment" refers to the act of providing care to a subject in need thereof, for the purpose of improving the health and / or well-being of the subject, with respect to an existing condition (e.g., disease, disorder) or with respect to preventing or reducing the likelihood of the occurrence of a condition, such as by administering a therapeutic agent (e.g., oligonucleotide) to the subject. In some embodiments, treatment includes reducing the frequency or severity of at least one sign, symptom, or contributing factor of a condition (e.g., disease, disorder) from which the subject suffers.

[0049] (II) Oligonucleotides

[0050] One aspect of the disclosure provides oligonucleotides with modification patterns that confer increased efficacy and / or duration to oligonucleotides. As used herein, modification patterns refer to the arrangement of modified nucleotides at certain positions in an oligonucleotide to enhance the efficacy and / or duration of an oligonucleotide (e.g., modifications performed with 2'-F or 2'-OMe at certain positions in an oligonucleotide). Modification patterns disclosed herein can be incorporated into oligonucleotides with any sequence (e.g., oligonucleotides targeting any sequence) to enhance their efficacy and / or duration.

[0051] In some embodiments, the oligonucleotides provided herein include a sense strand (also referred to as a passenger strand) and an antisense strand (also referred to as a guide strand) as separate strands. In some embodiments, the sense strand has a first region (R1) and a second region (R2), wherein the second region includes a first subregion (S1), a second subregion (S2), and a tetraloop (L) or triloop (triL) joining the first and second regions. In some embodiments, the first and second regions form a second duplex (D2). The second duplex (D2) may have different lengths. In some embodiments, the length of the second duplex (D2) is 1 to 6 base pairs. In some embodiments, the length of the second duplex (D2) is 2 to 6, 3 to 6, 4 to 6, 5 to 6, 1 to 5, 2 to 5, 3 to 5, or 4 to 5 base pairs. In some embodiments, the length of the second duplex (D2) is 1, 2, 3, 4, 5, or 6 base pairs.

[0052] In some embodiments, the first duplex (D1) is formed by the first district of the sense strand and the antisense strand. The first duplex (D1) may have different lengths. In some embodiments, the length of the first duplex (D1) is 12 to 20 base pairs. In some embodiments, the length of the first duplex (D1) is 13 to 20, 14 to 20, 15 to 20, 16 to 20, 17 to 20, 18 to 20 or 19 to 20 base pairs. In some embodiments, the length of the first duplex (D1) is 12 to 19, 12 to 18, 12 to 17, 12 to 16, 12 to 15, 12 to 14 or 12 to 13 base pairs in length. In some embodiments, the length of the first duplex (D1) is 12, 13, 14, 15, 16, 17, 18, 19 or 20 base pairs.

[0053] The first duplex (D1) or the second duplex (D2) may comprise at least one bicyclic nucleotide or locked nucleic acid (LNA). Locked nucleic acids or LNA are well known to the skilled artisan (Elman et al., 2005; Kurreck et al., 2002; Crinelli et al., 2002; Braasch and Corey, 2001; Bondensgaard et al., 2000; Wahlestedt et al., 2000). In some embodiments, the first duplex (D1) comprises at least one bicyclic nucleotide. In some embodiments, the second duplex (D2) comprises at least one bicyclic nucleotide.

[0054] In some embodiments, the oligonucleotide comprising sense strand and antisense strand provided herein has an asymmetric structure. In some embodiments, the oligonucleotide has an asymmetric structure, wherein the length of the sense strand is 36 nucleotides, and the length of the antisense strand is 22 nucleotides, wherein there are 2 single-stranded nucleotides (also referred to as 2 nucleotide 3'-overhangs) at its 3'-end. In some embodiments, the oligonucleotide has an asymmetric structure, wherein the length of the sense strand is 35 nucleotides, and the length of the antisense strand is 21 nucleotides, wherein there are 2 single-stranded nucleotides at its 3'-end. In some embodiments, the oligonucleotide has an asymmetric structure, wherein the length of the sense strand is 37 nucleotides, and the length of the antisense strand is 23 nucleotides, wherein there are 2 single-stranded nucleotides (also referred to as 2 nucleotide 3'-overhangs) at its 3'-end.

[0055] As provided herein, the oligonucleotide with asymmetric structure can include single-stranded nucleotides of any length at its 3'-end. In some embodiments, the oligonucleotide has an asymmetric structure, wherein the length of the sense strand is 36 nucleotides, and the length of the antisense strand is 22 nucleotides, wherein there are 2 single-stranded nucleotides at its 3'-end. In some embodiments, the oligonucleotide has an asymmetric structure, wherein the length of the sense strand is 36 nucleotides, and the length of the antisense strand is 23 nucleotides, wherein there are 3 single-stranded nucleotides at its 3'-end. In some embodiments, the oligonucleotide includes at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8 or more single-stranded nucleotides at its 3'-end. In some embodiments, the oligonucleotide includes 2, 3, 4, 5, 6, 7, 8 or more single-stranded nucleotides at its 3'-end.

[0056] In some embodiments, there are one or more (e.g., 1, 2, 3, 4, 5) mismatches between the sense strand and the antisense strand in the oligonucleotides provided herein. If there is more than one mismatch between the sense strand and the antisense strand, they may be positioned or interspersed continuously (e.g., 2, 3 or more in a row) throughout the complementary region. In some embodiments, the first duplex (D1) contains one or more mismatches. In some embodiments, the second duplex (D2) contains one or more mismatches.

[0057] (i) Antisense strand

[0058] In some embodiments, the antisense strand of an oligonucleotide may be referred to as a "guide strand". For example, if the antisense strand can engage with the RNA-induced silencing complex (RISC) and bind to the Argonaute protein, or engage or bind to one or more similar factors and guide the silencing of the target gene, it may be referred to as a guide strand. In some embodiments, the sense strand that is complementary to the guide strand may be referred to as a "passenger strand".

[0059] The antisense strand disclosed herein may comprise 20 to 22 nucleotides in length. In some embodiments, the antisense strand comprises 20 to 21 nucleotides in length or 21 to 22 nucleotides in length. In some embodiments, the antisense strand comprises 20 nucleotides in length, 21 nucleotides in length, or 22 nucleotides in length. In some embodiments, the antisense strand is 20 nucleotides in length, 21 nucleotides in length, or 22 nucleotides in length.

[0060] As provided herein, the oligonucleotide with asymmetric structure may be included in the antisense strand of single-stranded nucleotides with any length at its 3'-end. In some embodiments, the antisense strand comprises at least 2 single-stranded nucleotides at its 3'-end. In some embodiments, the antisense strand comprises at least 0, 1, 2, 3, at least 4, at least 5, at least 6 or more single-stranded nucleotides at its 3'-end. In some embodiments, the antisense strand comprises 2 single-stranded nucleotides at its 3'-end. In some embodiments, the antisense strand comprises 3 single-stranded nucleotides at its 3'-end. In some embodiments, the antisense strand comprises 4 single-stranded nucleotides at its 3'-end. In some embodiments, the antisense strand comprises 5 single-stranded nucleotides at its 3'-end. In some embodiments, the antisense strand comprises 6 single-stranded nucleotides at its 3'-end.

[0061] In some embodiments, the oligonucleotides disclosed herein comprise a polypeptide according to Tables 1 to 10 (and Figures 1 to Fig.10 ) with a modification pattern described in any one of the 2'-F modified nucleotides. In some embodiments, the oligonucleotides disclosed herein comprise a nucleotide modified according to Tables 1 to 10 (and Figures 1 to Fig.10 ) are modified with 2'-F and 2'-OMe according to the modification pattern described in . In some embodiments, the oligonucleotides provided herein comprise an antisense strand having a sugar moiety of a nucleotide modified with 2'-F at position 5. In some embodiments, the oligonucleotides provided herein comprise an antisense strand having a sugar moiety of a nucleotide at position 5 modified with 2'-F and a sugar moiety of each of the remaining nucleotides of the antisense strand modified with a modification provided herein.

[0062] In some embodiments, the oligonucleotides provided herein comprise antisense strands having sugar moieties at positions 2 and 14 modified with 2'-F. In some embodiments, the oligonucleotides provided herein comprise antisense strands having sugar moieties at positions 2, 5, and 14 modified with 2'-F. In some embodiments, the oligonucleotides provided herein comprise antisense strands having sugar moieties at positions 1, 2, 5, and 14 modified with 2'-F. In some embodiments, the oligonucleotides provided herein comprise antisense strands having sugar moieties at positions 1, 2, 3, 5, 7, and 14 modified with 2'-F. In some embodiments, the oligonucleotides provided herein comprise antisense strands having sugar moieties at positions 1, 2, 3, 5, 10, and 14 modified with 2'-F.

[0063] In some embodiments, the oligonucleotides provided herein comprise an antisense strand having a sugar moiety of each of the nucleotides at positions 2, 5, and 14 of the antisense strand modified with 2'-F and a sugar moiety of each of the remaining nucleotides of the antisense strand modified with a modification selected from the group consisting of: 2'-O-propargyl, 2'-O-propylamino, 2'-amino, 2'-ethyl, 2'-aminoethyl (EA), 2'-O-methyl (2'-OMe), 2'-O-methoxyethyl (2'-MOE), 2'-O-[2-(methylamino)-2-oxoethyl] (2'-O-NMA), and 2'-deoxy-2'-fluoro-β-d-arabinoic acid (2'-FANA).

[0064] In some embodiments, the oligonucleotides provided herein comprise an antisense strand having a sugar moiety at each of the nucleotides at positions 1, 2, 5, and 14 of the antisense strand modified with 2'-F and a sugar moiety at each of the remaining nucleotides of the antisense strand modified with a modification selected from the group consisting of: 2'-O-propargyl, 2'-O-propylamino, 2'-amino, 2'-ethyl, 2'-aminoethyl (EA), 2'-O-methyl (2'-OMe), 2'-O-methoxyethyl (2'-MOE), 2'-O-[2-(methylamino)-2-oxoethyl] (2'-O-NMA), and 2'-deoxy-2'-fluoro-β-d-arabinoic acid (2'-FANA).

[0065] In some embodiments, the oligonucleotides provided herein comprise an antisense strand having a sugar moiety at each of the nucleotides at positions 1, 2, 3, 5, 7, and 14 of the antisense strand modified with 2'-F and a sugar moiety at each of the remaining nucleotides of the antisense strand modified with a modification selected from the group consisting of: 2'-O-propargyl, 2'-O-propylamino, 2'-amino, 2'-ethyl, 2'-aminoethyl (EA), 2'-O-methyl (2'-OMe), 2'-O-methoxyethyl (2'-MOE), 2'-O-[2-(methylamino)-2-oxoethyl] (2'-O-NMA), and 2'-deoxy-2'-fluoro-β-d-arabinoic acid (2'-FANA).

[0066] In some embodiments, the oligonucleotides provided herein comprise an antisense strand having a sugar moiety at each of the nucleotides at positions 1, 2, 3, 5, 10, and 14 of the antisense strand modified with 2'-F and a sugar moiety at each of the remaining nucleotides of the antisense strand modified with a modification selected from the group consisting of 2'-O-propargyl, 2'-O-propylamino, 2'-amino, 2'-ethyl, 2'-aminoethyl (EA), 2'-O-methyl (2'-OMe), 2'-O-methoxyethyl (2'-MOE), 2'-O-[2-(methylamino)-2-oxoethyl] (2'-O-NMA), and 2'-deoxy-2'-fluoro-β-d-arabinoic acid (2'-FANA).

[0067] In some embodiments, the oligonucleotides provided herein comprise an antisense strand having a sugar moiety at each of the nucleotides at positions 2, 3, 5, 7, 10, and 14 of the antisense strand modified with 2'-F and a sugar moiety at each of the remaining nucleotides of the antisense strand modified with a modification selected from the group consisting of 2'-O-propargyl, 2'-O-propylamino, 2'-amino, 2'-ethyl, 2'-aminoethyl (EA), 2'-O-methyl (2'-OMe), 2'-O-methoxyethyl (2'-MOE), 2'-O-[2-(methylamino)-2-oxoethyl] (2'-O-NMA), and 2'-deoxy-2'-fluoro-β-d-arabinoic acid (2'-FANA).

[0068] In some embodiments, the oligonucleotides provided herein comprise an antisense strand having a sugar moiety at position 1, position 2, position 3, position 4, position 5, position 6, position 7, position 8, position 9, position 10, position 11, position 12, position 13, position 14, position 15, position 16, position 17, position 18, position 19, position 20, position 21, or position 22 modified with 2'-F.

[0069] In some embodiments, the oligonucleotides provided herein comprise an antisense strand having a sugar moiety at position 1, position 2, position 3, position 4, position 5, position 6, position 7, position 8, position 9, position 10, position 11, position 12, position 13, position 14, position 15, position 16, position 17, position 18, position 19, position 20, position 21, or position 22 modified with 2'-OMe.

[0070] In some embodiments, the oligonucleotides provided herein comprise an antisense strand of a sugar moiety at position 1, position 2, position 3, position 4, position 5, position 6, position 7, position 8, position 9, position 10, position 11, position 12, position 13, position 14, position 15, position 16, position 17, position 18, position 19, position 20, position 21, or position 22 that is modified with a modification selected from the group consisting of: 2'-O-propargyl, 2'-O-propylamino, 2'-amino, 2'-ethyl, 2'-aminoethyl (EA), 2'-O-methyl (2'-OMe), 2'-O-methoxyethyl (2'-MOE), 2'-O-[2-(methylamino)-2-oxoethyl] (2'-O-NMA), and 2'-deoxy-2'-fluoro-β-d-arabinoic acid (2'-FANA).

[0071] (ii) Sense strand

[0072] In some embodiments, an oligonucleotide provided herein may comprise an antisense strand and a sense strand.

[0073] In some embodiments, the sense strand comprises 17 to 36 nucleotides in length. In some embodiments, the sense strand is 17 nucleotides in length, 18 nucleotides in length, 19 nucleotides in length, 20 nucleotides in length, 21 nucleotides in length, 22 nucleotides in length, 23 nucleotides in length, 24 nucleotides in length, 25 nucleotides in length, 26 nucleotides in length, 27 nucleotides in length, 28 nucleotides in length, 29 nucleotides in length, 30 nucleotides in length, 31 nucleotides in length, 32 nucleotides in length, 33 nucleotides in length, 34 nucleotides in length, 35 nucleotides in length, or 36 nucleotides in length.

[0074] In some embodiments, the sense strand has a first region (R1) and a second region (R2), wherein the second region comprises a first subregion (S1) and a second subregion (S2) to form a second duplex (D2). In some embodiments, the length of the second duplex (D2) formed between the first subregion (S1) and the second subregion (S2) is at least 1 (e.g., at least 2, at least 3, at least 4, at least 5, or at least 6) base pairs. In some embodiments, the length of the duplex formed between the first subregion (S1) and the second subregion (S2) is in the range of 1 to 6 base pairs (e.g., a length of 1 to 5, 1 to 4, 1 to 3, 1 to 2, 2 to 6, 3 to 6, 4 to 6, or 5 to 6 base pairs).

[0075] In some embodiments, the second region (R2) comprises a tetraloop (L) or a triloop (triL) joining the first and second regions. In some embodiments, the tetraloop or triloop is at the 3' end of the sense strand. In some embodiments, the tetraloop or triloop is at the 5' end of the antisense strand.

[0076] Any number of nucleotides in the triloop or tetraloop may be conjugated to a targeting ligand. In some embodiments, the triloop comprises 1 nucleotide conjugated to a ligand. In some embodiments, the triloop comprises 2 nucleotides conjugated to a ligand. In some embodiments, the triloop comprises 3 nucleotides conjugated to a ligand. In some embodiments, the triloop comprises 1 to 3 nucleotides conjugated to a ligand. In some embodiments, the triloop comprises 1 to 2 nucleotides conjugated to a ligand or 2 to 3 nucleotides conjugated to a ligand.

[0077] In some embodiments, the tetraloop comprises 1 nucleotide conjugated to a ligand. In some embodiments, the tetraloop comprises 2 nucleotides conjugated to a ligand. In some embodiments, the tetraloop comprises 3 nucleotides conjugated to a ligand. In some embodiments, the tetraloop comprises 4 nucleotides conjugated to a ligand. In some embodiments, the tetraloop comprises 1 to 4 nucleotides conjugated to a ligand. In some embodiments, the tetraloop comprises 1 to 3 nucleotides, 1 to 2 nucleotides, 2 to 4 nucleotides, or 3 to 4 nucleotides conjugated to a ligand.

[0078] In some embodiments, the tetracyclic or tricyclic rings may contain ribonucleotides, deoxyribonucleotides, modified nucleotides, and combinations thereof. Non-limiting examples of RNA tetracyclic rings include, but are not limited to, UNCG tetracyclic ring families (e.g., UUCG), GNRA tetracyclic ring families (e.g., GAAA), and CUUG tetracyclic rings. Non-limiting examples of DNA tetracyclic rings include, but are not limited to, d(GNNA) tetracyclic ring families (e.g., d(GTTA)), d(GNRA) tetracyclic ring families, d(GNAB) tetracyclic ring families, d(CNNG) tetracyclic ring families, and d(TNCG) tetracyclic ring families (e.g., d(TTCG)).

[0079] In some embodiments, the oligonucleotides disclosed herein comprise a polypeptide according to Tables 1 to 10 (and Figures 1 to Fig.10 ) with a sense strand of nucleotides modified with 2'-F according to the modification pattern described in any one of Tables 1 to 10 (and Figures 1 to Fig.10 ) with the sense strand of nucleotides modified with 2'-F and 2'-OMe according to the modification pattern described in .

[0080] In some embodiments, the oligonucleotides provided herein comprise a sense strand having a sugar moiety at positions 8 to 11 modified with 2'-F. In some embodiments, the oligonucleotides provided herein comprise a sense strand having a sugar moiety at positions 1 to 7 and 12 to 17 or 12 to 20 modified with 2'OMe. In some embodiments, the oligonucleotides provided herein comprise a sense strand having a sugar moiety at each of the nucleotides at positions 1 to 7 and 12 to 17 or 12 to 20 of the sense strand modified with a modification selected from the group consisting of 2'-O-propargyl, 2'-O-propylamino, 2'-amino, 2'-ethyl, 2'-aminoethyl (EA), 2'-O-methyl (2'-OMe), 2'-O-methoxyethyl (2'-MOE), 2'-O-[2-(methylamino)-2-oxoethyl] (2'-O-NMA), and 2'-deoxy-2'-fluoro-β-d-arabinoic acid (2'-FANA).

[0081] In some embodiments, the oligonucleotides provided herein comprise a sense strand having a sugar moiety at position 1, position 2, position 3, position 4, position 5, position 6, position 7, position 8, position 9, position 10, position 11, position 12, position 13, position 14, position 15, position 16, position 17, position 18, position 19, position 20, position 21, position 22, position 23, position 24, position 25, position 26, position 27, position 28, position 29, position 30, position 31, position 32, position 33, position 34, position 35, or position 36 modified with 2'-F.

[0082] In some embodiments, the oligonucleotides provided herein comprise a sense strand having a sugar moiety at position 1, position 2, position 3, position 4, position 5, position 6, position 7, position 8, position 9, position 10, position 11, position 12, position 13, position 14, position 15, position 16, position 17, position 18, position 19, position 20, position 21, position 22, position 23, position 24, position 25, position 26, position 27, position 28, position 29, position 30, position 31, position 32, position 33, position 34, position 35, or position 36 modified with 2'-OMe.

[0083] In some embodiments, the oligonucleotides provided herein comprise positions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75 , the sense strand of the sugar moiety at position 31, position 32, position 33, position 34, position 35 or position 36: 2'-O-propargyl, 2'-O-propylamino, 2'-amino, 2'-ethyl, 2'-aminoethyl (EA), 2'-O-methyl (2'-OMe), 2'-O-methoxyethyl (2'-MOE), 2'-O-[2-(methylamino)-2-oxoethyl] (2'-O-NMA) and 2'-deoxy-2'-fluoro-β-d-arabinoic acid (2'-FANA).

[0084] (iii) Oligonucleotide modification

[0085] Oligonucleotides can be modified in various ways to improve or control specificity, stability, delivery, bioavailability, resistance to nuclease degradation, immunogenicity, base pairing properties, RNA distribution and cellular uptake and other features related to treatment or research purposes. See, for example, Bramsen et al., NUCLEIC ACIDS RES., 2009, 37, 2867-2881; Bramsen and Kjems (FRONTIERS IN GENETICS, 3 (2012): 1-22). Therefore. Some embodiments may include one or more suitable modifications. In some embodiments, the modified nucleotide has a modification in its base (or nucleobase), sugar (e.g., ribose, deoxyribose) or phosphate group.

[0086] The number of modifications on the oligonucleotide and the positions of those nucleotide modifications can affect the properties of the oligonucleotide. For example, the oligonucleotide can be delivered in vivo by conjugating it to a lipid nanoparticle (LNP) or a similar carrier or by being included in a lipid nanoparticle (LNP) or a similar carrier. However, when the oligonucleotide is not protected by LNP or a similar carrier, it may be advantageous to modify at least some of its nucleotides. Therefore, in some embodiments of any one of the oligonucleotides provided herein, the nucleotides of all or substantially all of the oligonucleotides are modified. In certain embodiments, more than half of the nucleotides are modified. In certain embodiments, less than half of the nucleotides are modified. Typically, in the case of naked delivery, each sugar is modified at the 2'-position. These modifications may be reversible or irreversible. In some embodiments, the oligonucleotides as disclosed herein have a certain number and type of modified nucleotides that are sufficient to produce desired characteristics (e.g., to prevent enzymatic degradation, the ability of targeting desired cells after in vivo administration, and / or thermodynamic stability).

[0087] (a) Sugar modification

[0088] In some embodiments, the modified sugar (also referred to herein as a sugar analog) includes a modified deoxyribose or ribose moiety, for example, wherein one or more modifications occur at the 2', 3', 4' and / or 5' carbon position of the sugar. In some embodiments, the modified sugar may also include non-natural alternative carbon structures, such as those present in locked nucleic acids ("LNA") (see, e.g., Koshkin et al., (1998), TETRAHEDRON 54, 3607-3630), unlocked nucleic acids ("UNA") (see, e.g., Snead et al., (2013), MOLECULAR THERAPY-NUCLEIC ACIDS, 2, e103) and bridged nucleic acids ("BNA") (see, e.g., Imanishi and Obika (2002), The Royal Society of Chemistry, CHEM. COMMUN., 1653-1659). Koshkin et al., Snead et al., and Imanishi and Obika are incorporated herein by reference for their disclosures related to sugar modifications.

[0089] In some embodiments, the nucleotide modification of the sugar comprises a 2'-modification. In some embodiments, the 2'-modification may be 2'-O-propargyl, 2'-O-propylamino, 2'-amino, 2'-ethyl, 2'-aminoethyl (EA), 2'-O-methyl (2'-OMe), 2'-O-methoxyethyl (2'-MOE), 2'-O-[2-(methylamino)-2-oxoethyl] (2'-O-NMA) and 2'-deoxy-2'-fluoro-β-d-arabinoic acid (2'-FANA). In some embodiments, the modification is 2'-fluoro, 2'-O-methyl or 2'-O-methoxyethyl. In some embodiments, the modification of the sugar comprises a modification of the sugar ring, which may comprise a modification of one or more carbons of the sugar ring. For example, the sugar modification of the nucleotide may comprise a 2'-oxygen of a sugar connected to the 1'-carbon or 4'-carbon of the sugar, or a 2'-oxygen of a 1'-carbon or 4'-carbon connected via an ethylene or methylene bridge. In some embodiments, the modified nucleotide has an acyclic sugar lacking a 2'-carbon and 3'-carbon bond. In some embodiments, the modified nucleotide has a thiol group, for example, at the 4' position of the sugar.

[0090] In some embodiments, the oligonucleotides described herein comprise at least one modified nucleotide (e.g., at least 1, at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, or more). In some embodiments, the sense strand of the oligonucleotide comprises at least one modified nucleotide (e.g., at least 1, at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, or more). In some embodiments, the antisense strand of the oligonucleotide comprises at least one modified nucleotide (e.g., at least 1, at least 5, at least 10, at least 15, at least 20, or more).

[0091] In some embodiments, all nucleotides of the sense strand of an oligonucleotide are modified. In some embodiments, all nucleotides of the antisense strand of an oligonucleotide are modified. In some embodiments, all nucleotides of an oligonucleotide (i.e., both the sense strand and the antisense strand) are modified. In some embodiments, the modified nucleotides comprise 2'-modifications (e.g., 2'-fluoro or 2'-O-methyl, 2'-O-methoxyethyl, and 2'-deoxy-2'-fluoro-β-d-arabinoic acid). In some embodiments, the modified nucleotides comprise 2'-modifications (e.g., 2'-fluoro or 2'-O-methyl).

[0092] The present disclosure provides oligonucleotides with different modification patterns. In some embodiments, the modified oligonucleotides include oligonucleotides having the following modification patterns: Fig.10 ) and a sense strand sequence having a modification pattern as described in any one of Tables 1 to 10 (and Figures 1 to Fig.10 ) In some embodiments, for these oligonucleotides, one or more of positions 8, 9, 10, or 11 of the sense strand are modified with a 2'-F group. In other embodiments, for these oligonucleotides, the sugar moiety of each of the nucleotides at positions 1 to 7 and 12 to 20 in the sense strand is modified with a 2'-O-methyl group.

[0093] In some embodiments, the present invention provides an oligonucleotide that is or comprises a modified or unmodified sense strand selected from those listed in Table A. In some embodiments, the present invention provides an oligonucleotide that is or comprises a modified or unmodified antisense strand selected from those listed in Table A. In some embodiments, the present invention provides a modified or unmodified double-stranded oligonucleotide selected from those listed in Table A. In some embodiments, the present invention provides a sense strand modification pattern selected from those listed in Table A. In some embodiments, the present invention provides an antisense strand modification pattern selected from those listed in Table A.

[0094]

[0095]

[0096]

[0097]

[0098]

[0099]

[0100]

[0101]

[0102]

[0103]

[0104]

[0105]

[0106]

[0107]

[0108]

[0109]

[0110]

[0111]

[0112]

[0113]

[0114]

[0115]

[0116]

[0117]

[0118] In some embodiments, the antisense strand has 3 nucleotides modified with 2'-F at the 2'-position of the sugar moiety. In some embodiments, the sugar moieties at positions 2, 5, and 14 of the antisense strand and optionally up to 3 nucleotides at positions 1, 3, 7, and 10 are modified with 2'-F. In other embodiments, the sugar moieties at each of the positions at positions 2, 5, and 14 of the antisense strand are modified with 2'-F. In other embodiments, the sugar moieties at each of the positions at positions 1, 2, 5, and 14 of the antisense strand are modified with 2'-F. In yet other embodiments, the sugar moieties at each of the positions at positions 1, 2, 3, 5, 7, and 14 of the antisense strand are modified with 2'-F. In yet another embodiment, the sugar moieties at each of the positions at positions 1, 2, 3, 5, 10, and 14 of the antisense strand are modified with 2'-F. In another embodiment, the sugar moieties at each of the positions at positions 2, 3, 5, 7, 10, and 14 of the antisense strand are modified with 2'-F.

[0119] (b) 5' terminal phosphate

[0120] In some embodiments, the 5'-terminal phosphate group of the oligonucleotide enhances the interaction with Argonaute2. However, oligonucleotides comprising 5'-phosphate groups can be easily degraded via phosphatases or other enzymes, which can limit their in vivo bioavailability. In some embodiments, oligonucleotides include analogs of 5' phosphates that are resistant to such degradation. In some embodiments, the phosphate analogs can be oxymethylphosphonates, vinylphosphonates, or malonylphosphonates. In certain embodiments, the 1' end of the oligonucleotide chain is connected to a chemical portion that simulates the electrostatic and steric properties of a natural 5'-phosphate group ("phosphate mimics").

[0121] In some embodiments, the oligonucleotide has a phosphate analog at the 4' carbon position of the sugar (referred to as a "4'-phosphate analog"). See, for example, International Patent Application PCT / US2017 / 049909 filed on September 1, 2017, U.S. Provisional Application No. 62 / 383,207, entitled 4'-Phosphate Analogs and Oligonucleotides Comprising the Same, filed on September 2, 2016, and U.S. Provisional Application No. 62 / 393,401, entitled 4'-Phosphate Analogs and Oligonucleotides Comprising the Same, filed on September 12, 2016, each of which is incorporated herein by reference for its contents related to phosphate analogs. In some embodiments, the oligonucleotides provided herein include a 4'-phosphate analog at the 5'-terminal nucleotide. In some embodiments, the phosphate analog is an oxymethylphosphonate, wherein the oxygen atom of the oxymethyl group is bound to a sugar moiety (e.g., at its 4' carbon) or an analog thereof. In other embodiments, the 4'-phosphate analog is a thiomethylphosphonate or an aminomethylphosphonate, wherein the sulfur atom of the thiomethyl or the nitrogen atom of the aminomethyl is bound to the 4'-carbon of the sugar moiety or its analog. In certain embodiments, the 4'-phosphate analog is an oxymethylphosphonate. In some embodiments, the oxymethylphosphonate is represented by the formula -O-CH2-PO(OH)2 or -O-CH2-PO(OR)2, wherein R is independently selected from H, CH3, alkyl, CH2CH2CN, CH2OCOC(CH3)3, CHOCH2CH2Si(CH3)3 or a protecting group. In certain embodiments, the alkyl is CH2CH3. More generally, R is independently selected from H, CH3 or CH2CH3.

[0122] (c). Modified intranucleoside linkages

[0123] In some embodiments, the oligonucleotide may comprise a modified internucleoside linkage. In some embodiments, phosphate modification or substitution may produce an oligonucleotide comprising at least one (e.g., at least 1, at least 2, at least 3, or at least 5) modified internucleotide linkages. In some embodiments, any of the oligonucleotides disclosed herein comprises 1 to 10 (e.g., 1 to 10, 2 to 8, 4 to 6, 3 to 10, 5 to 10, 1 to 5, 1 to 3, or 1 to 2) modified internucleotide linkages. In some embodiments, any of the oligonucleotides disclosed herein comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 modified internucleotide linkages.

[0124] The modified internucleotide linkage can be a phosphorodithioate linkage, a phosphorothioate linkage, a phosphotriester linkage, an alkylthiophosphonate linkage, an alkylthiophosphonate triester linkage, a phosphoramidite linkage, a phosphonate linkage, or a boranophosphate linkage. In some embodiments, at least one modified internucleotide linkage of any of the oligonucleotides disclosed herein is a phosphorothioate linkage.

[0125] In some embodiments, the oligonucleotides described herein have a phosphorothioate linkage between one or more of positions 1 and 2 of the sense strand, positions 1 and 2 of the antisense strand, positions 2 and 3 of the antisense strand, positions 3 and 4 of the antisense strand, positions 20 and 21 of the antisense strand, and positions 21 and 22 of the antisense strand. In some embodiments, the oligonucleotides described herein have a phosphorothioate linkage between each of positions 1 and 2 of the sense strand, positions 1 and 2 of the antisense strand, positions 2 and 3 of the antisense strand, positions 20 and 21 of the antisense strand, and positions 21 and 22 of the antisense strand.

[0126] (d) Base modification

[0127] In some embodiments, the oligonucleotides provided herein have one or more modified nucleobases. In some embodiments, the modified nucleobase (also referred to herein as base analogs) is connected to the 1' position of the nucleotide sugar moiety. In certain embodiments, the modified nucleobase is a nitrogenous base. In certain embodiments, the modified nucleobase does not contain a nitrogen atom. See, for example, U.S. Published Patent Application No. 20080274462. In some embodiments, the modified nucleotides include universal bases. However, in certain embodiments, the modified nucleotides do not contain nucleobases (abase).

[0128] In some embodiments, the universal base is a heterocyclic moiety located at the 1' position of the nucleotide sugar moiety in the modified nucleotide or at an equivalent position in a nucleotide sugar moiety substitution that can be positioned opposite to more than one type of base when present in a duplex without substantially changing the structure of the duplex. In some embodiments, a single-stranded nucleic acid containing a universal base forms a duplex with a target nucleic acid that has a lower T value than a duplex formed with a complementary nucleic acid, compared to a reference single-stranded nucleic acid (e.g., an oligonucleotide) that is completely complementary to the target nucleic acid. m However, in some embodiments, compared to a reference single-stranded nucleic acid in which the universal base has been base-substituted to produce a single mismatch, the single-stranded nucleic acid containing the universal base forms a duplex with the target nucleic acid that has a higher T value than the duplex formed with the nucleic acid containing the mismatched base. m .

[0129] Non-limiting examples of universal binding nucleotides include inosine, 1-β-D-ribofuranosyl-5-nitroindole and / or 1-β-D-ribofuranosyl-3-nitropyrrole (U.S. Patent Application Publication No. 20070254362 to Quay et al.; Van Aerschot et al., An acyclic 5-nitroindazole nucleoside analogue as ambiguousnucleoside. NUCLEIC ACIDS RES. 1995 Nov 11; 23(21):4363-70; Loakes et al., 3-Nitropyrrole and 5-nitroindole as universal bases in primers for DNA sequencing and PCR. NUCLEIC ACIDS RES. 1995 Jul 11; 23(13):2361-6; Loakes and Brown, 5-Nitroindole as a universal base analogue, NUCLEIC ACIDS RES. 1994 Oct 11;22(20):4039-43. The disclosures of the foregoing with respect to base modifications are incorporated herein by reference).

[0130] (e) Reversible modification

[0131] Although certain modifications can be made to protect the oligonucleotide from the in vivo environment before reaching the target cell, the modifications can reduce the effectiveness or activity of the oligonucleotide after the oligonucleotide reaches the cytosol of the target cell. Reversible modifications can be made so that the molecule retains the desired properties outside the cell and then removed when entering the cytosolic environment of the cell. Reversible modifications can be removed, for example, by the action of intracellular enzymes or by chemical conditions inside the cell (e.g., reduction by intracellular glutathione).

[0132] In some embodiments, the reversibly modified nucleotide comprises a glutathione-sensitive moiety. Typically, nucleic acid molecules have been chemically modified with cyclic disulfide moieties to mask the negative charge generated by the internucleotide diphosphate linkage and improve cellular uptake and nuclease resistance. See U.S. Published Application No. 2011 / 0294869, originally assigned to Traversa Therapeutics, Inc. ("Traversa"); PCT Publication No. WO 2015 / 188197 of Solstice Biologics, Ltd. ("Solstice"); Meade et al., NATURE BIOTECHNOLOGY, 2014, 32: 1256-1263 ("Meade"); PCT Publication No. WO 2014 / 088920 of Merck Sharp & Dohme Corp, each of which is incorporated herein by reference for its disclosure of such modifications. This reversible modification of the internucleotide diphosphate linkage is designed to be cleaved intracellularly by the reducing environment of the cytosol (e.g., glutathione). Early examples include neutralization of phosphotriester modifications reported to be cleavable inside cells (Dellinger et al., J. AM. CHEM. SOC. 2003, 125: 940-950).

[0133] In some embodiments, when the oligonucleotide is exposed to nuclease and other harsh environmental conditions (e.g., pH), this reversible modification is protected during in vivo administration (e.g., transferred to the lysosome / endosome compartment of blood and / or cells). When released into the cytosol of cells with a higher glutathione content than the extracellular space, the modification is reversed, and the resulting product is a cracked oligonucleotide. Compared with the options available using irreversible chemical modifications, using reversible glutathione sensitive parts, it is possible to introduce spatially larger chemical groups into the target oligonucleotide. This is because these larger chemical groups will be removed in the cytosol, and therefore the biological activity of the oligonucleotide inside the cytosol of the cell should not be disturbed. Therefore, these larger chemical groups can be engineered to give nucleotides or oligonucleotides various advantages, such as nuclease resistance, lipophilicity, charge, thermal stability, specificity and reduced immunogenicity. In some embodiments, the structure of the glutathione sensitive part can be engineered to change the kinetics of its release.

[0134] In some embodiments, the glutathione sensitive part is connected to the sugar of the nucleotide. In some embodiments, the glutathione sensitive part is connected to the 2'-carbon of the sugar of the modified nucleotide. In some embodiments, the glutathione sensitive part is located at the 5'-carbon of the sugar, especially when the modified nucleotide is the 5'-terminal nucleotide of the oligonucleotide. In some embodiments, the glutathione sensitive part is located at the 3'-carbon of the sugar, especially when the modified nucleotide is the 3'-terminal nucleotide of the oligonucleotide. In some embodiments, the glutathione sensitive part comprises a sulfonyl group. See, for example, U.S. Provisional Application No. 62 / 378,635 entitled Compositions Comprising Reversibly Modified Oligonucleotidesand Uses Thereof, filed on August 23, 2016, and with respect to its related disclosures, the contents of which are incorporated herein by reference.

[0135] (iv) Targeting ligand

[0136] In some embodiments, it may be necessary to target one or more cells or one or more organs of the oligonucleotide disclosed herein. This strategy may help avoid the undesired effects in other organs or may avoid the undue loss of oligonucleotides to cells, tissues or organs that will not benefit from the oligonucleotides. Therefore, in some embodiments, the oligonucleotides disclosed herein may be modified to help the targeting of specific tissues, cells or organs, such as to help the oligonucleotides be delivered to the liver. In certain embodiments, the oligonucleotides disclosed herein may be modified to help the oligonucleotides be delivered to the hepatocytes of the liver. In some embodiments, the oligonucleotides comprise nucleotides conjugated to one or more targeting ligands.

[0137] The targeting ligand may comprise a carbohydrate, an amino sugar, cholesterol, a peptide, a polypeptide, a protein or a portion of a protein (e.g., an antibody or antibody fragment) or a lipid. In some embodiments, the targeting ligand is an aptamer. For example, the targeting ligand may be an RGD peptide for targeting tumor vasculature or glioma cells, a CREKA peptide for targeting tumor vasculature or pores, transferrin, lactoferrin, or an aptamer targeting transferrin receptors expressed on CNS vasculature, or an anti-EGFR antibody targeting EGFR on glioma cells. In certain embodiments, the targeting ligand is one or more GalNAc moieties.

[0138] In some embodiments, 1 or more (e.g., 1, 2, 3, 4, 5, or 6) nucleotides of an oligonucleotide are each conjugated to a separate targeting ligand. In some embodiments, 2 to 4 nucleotides of an oligonucleotide are each conjugated to a separate targeting ligand. In some embodiments, a targeting ligand is conjugated to 2 to 4 nucleotides at either end of a sense strand or antisense strand (e.g., a ligand is conjugated to 2 to 4 nucleotides at the 5' or 3' end of a sense strand or antisense strand) so that the targeting ligand is similar to the bristles of a toothbrush and the oligonucleotide is similar to a toothbrush. For example, an oligonucleotide may include a stem loop at the 5' or 3' end of a sense strand and 1, 2, 3, or 4 nucleotides of the stem loop may be conjugated to a targeting ligand individually.

[0139] GalNAc is a high affinity ligand for the asialoglycoprotein receptor (ASGPR), which is primarily expressed on the sinusoidal surface of hepatocytes and plays a major role in the binding, internalization, and subsequent clearance of circulating glycoproteins containing terminal galactose or N-acetylgalactosamine residues (asialoglycoproteins). Conjugation (indirect or direct) of the GalNAc moiety to the oligonucleotides of the present disclosure can be used to target these oligonucleotides to ASGPR expressed on cells.

[0140] In some embodiments, the oligonucleotides of the present disclosure are directly or indirectly conjugated to monovalent GalNAc. In some embodiments, the oligonucleotides are directly or indirectly conjugated to more than one monovalent GalNAc (i.e., conjugated to 2, 3 or 4 monovalent GalNAc moieties, and usually conjugated to 3 or 4 monovalent GalNAc moieties). In some embodiments, the oligonucleotides of the present disclosure are conjugated to one or more divalent GalNAc, trivalent GalNAc or tetravalent GalNAc moieties.

[0141] In some embodiments, 1 or more (e.g., 1, 2, 3, 4, 5, or 6) nucleotides of an oligonucleotide are each conjugated to a GalNAc moiety. In some embodiments, 2 to 4 nucleotides of a tetracyclic ring are each conjugated to a separate GalNAc. In some embodiments, 1 to 3 nucleotides of a tricyclic ring are each conjugated to a separate GalNAc. In some embodiments, a targeting ligand is conjugated to 2 to 4 nucleotides at either end of a sense strand or antisense strand (e.g., a ligand is conjugated to 2 to 4 nucleotides on the 5' or 3' end of a sense strand or antisense strand) so that the GalNAc moiety is similar to the bristles of a toothbrush and the oligonucleotide is similar to a toothbrush. In some embodiments, a GalNAc moiety is conjugated to a nucleotide of a sense strand. For example, four GalNAc moieties may be conjugated to nucleotides in the tetracyclic ring of a sense strand, wherein each GalNAc moiety is conjugated to a nucleotide.

[0142] In some embodiments, the oligonucleotides herein comprise a monovalent GalNAc linked to a guanidine nucleotide, referred to as [ademG-GalNAc] or 2'-aminodiethoxymethanol-guanidine-GalNAc, as depicted below:

[0143]

[0144] In some embodiments, the oligonucleotides herein comprise a monovalent GalNAc linked to an adenine nucleotide, referred to as [ademA-GalNAc] or 2'-aminodiethoxymethanol-adenine-GalNAc, as depicted below.

[0145]

[0146] An example of such a conjugation is shown below, showing a loop from 5' to 3' comprising the nucleotide sequence GAAA (L = linker, X = heteroatom) stem attachment point. Such a loop may be present in, for example Figure 1A 27 to 30 of the molecule shown in FIG. In the chemical formula, Used to describe the point of attachment to an oligonucleotide chain.

[0147]

[0148] Appropriate methods or chemistry (e.g., click chemistry) can be used to connect the targeting ligand to the nucleotide. In some embodiments, the targeting ligand is conjugated to the nucleotide using a click linker. In some embodiments, an acetal-based linker is used to conjugate the targeting ligand to the nucleotide of any one of the oligonucleotides described herein. Acetal-based linkers are disclosed in, for example, International Patent Application Publication No. WO2016100401 A1, published on June 23, 2016, and the contents are incorporated herein by reference in their entirety. In some embodiments, the linker is an unstable linker. However, in other embodiments, the linker is stable.

[0149] An example is shown below for a loop comprising nucleotides GAAA from 5' to 3', wherein the GalNac moiety is linked to the nucleotides of the loop using an acetal linker. Such a loop may be present, for example, in Fig.10 In the chemical formula, It is the point of attachment to the oligonucleotide chain.

[0150]

[0151] Any suitable method or chemistry (e.g., click chemistry) can be used to connect the targeting ligand to the nucleotide. In some embodiments, the targeting ligand is conjugated to the nucleotide using a click linker. In some embodiments, an acetal-based linker is used to conjugate the targeting ligand to the nucleotide of any one of the oligonucleotides described herein. Acetal-based linkers are disclosed in, for example, International Patent Application Publication No. WO2016100401 A1, published on June 23, 2016, and the contents of such linkers are incorporated herein by reference. In some embodiments, the linker is an unstable linker. However, in other embodiments, the linker is stable. "Unstable linker" refers to a linker that can be, for example, cleaved by acidic pH. "Extremely stable linker" refers to a non-cleavable linker.

[0152] In some embodiments, a duplex extension portion (e.g., up to 3, 4, 5, or 6 base pairs in length) is generated between the targeting ligand (e.g., a GalNAc portion) and the double-stranded oligonucleotide. In some embodiments, the oligonucleotides of the present disclosure do not have conjugated GalNAc.

[0153] III. Preparation

[0154] Various preparations have been developed to promote the use of oligonucleotides. For example, oligonucleotides can be delivered to a subject or a cellular environment using preparations that minimize degradation, promote delivery and / or uptake, or provide another beneficial property for the oligonucleotides in the preparation. In some embodiments, the oligonucleotides are formulated in buffer solutions such as phosphate buffered saline solutions, liposomes, micelle structures, and capsids.

[0155] Preparations of oligonucleotides and cationic lipids can be used to facilitate transfection of oligonucleotides into cells. For example, cationic lipids (such as liposomes), cationic glycerol derivatives, and polycationic molecules (e.g., polylysine) can be used. Suitable lipids include Oligofectamine, Lipofectamine (Life Technologies), NC388 (Ribozyme Pharmaceuticals, Inc., Boulder, Colo.) or FuGene 6 (Roche), all of which can be used according to the manufacturer's instructions.

[0156] Thus, in some embodiments, the formulation comprises lipid nanoparticles. In some embodiments, the excipient comprises a liposome, a lipid, a lipid complex, a microsphere, a microparticle, a nanosphere or a nanoparticle, or can be otherwise formulated for administration to a cell, a tissue, an organ or a body of a subject in need thereof (see, e.g., Remington: THE SCIENCE AND PRACTICE OF PHARMACY, 22nd ed., Pharmaceutical Press, 2013).

[0157] In some embodiments, the formulation as disclosed herein comprises an excipient. In some embodiments, the excipient imparts improved stability, improved absorption, improved solubility and / or therapeutic enhancement of the active ingredient to the composition. In some embodiments, the excipient is a buffer (e.g., sodium citrate, sodium phosphate, tris alkali or sodium hydroxide) or a vehicle (e.g., a buffer solution, vaseline, dimethyl sulfoxide or mineral oil). In some embodiments, the oligonucleotide is lyophilized to extend its shelf life and then made into a solution (e.g., administered to a subject) before use. Therefore, the excipient in the composition comprising any one of the oligonucleotides described herein may be a lyoprotectant (e.g., mannitol, lactose, polyethylene glycol or polyvinyl pyrrolidone), or a disintegration temperature regulator (e.g., dextran, polysucrose or gelatin).

[0158] In some embodiments, the pharmaceutical composition is formulated to be compatible with its intended route of administration.Examples of routes of administration include parenteral, such as intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration.

[0159] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (in the case of water soluble) or dispersions and sterile powders for the temporary preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, antibacterial water, Cremophor EL.TM. (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). The carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol and liquid polyethylene glycol, etc.) and suitable mixtures thereof. In many cases, isotonic agents, such as sugars, polyols (such as mannitol, sorbitol) or sodium chloride will preferably be included in the composition. A sterile injectable solution can be prepared by incorporating the oligonucleotides into a selected solvent in the desired amount with a composition or combination of components listed above, followed by filtration sterilization (as required).

[0160] In some embodiments, the composition may contain at least about 0.1% of the therapeutic agent or more, but the percentage of active ingredient may be between about 1% and 80% or more of the weight or volume of the total composition. Those skilled in the art who prepare such pharmaceutical formulations will consider factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life, and other pharmacological considerations, and therefore, various dosages and treatment regimens may be desirable.

[0161] Even though the various embodiments relate to targeted liver delivery of any of the oligonucleotides disclosed herein, targeting other tissues is also contemplated.

[0162] IV. How to use

[0163] (a) Reduce RNA expression in cells

[0164] In some embodiments, for the purpose of reducing the expression of RNA in cells, there is provided a method for delivering an effective amount of any one of the oligonucleotides disclosed herein to cells. The method provided herein is applicable to any appropriate cell type. In some embodiments, the cell is any cell expressing RNA (for example, hepatocytes, macrophages, cells derived from monocytes, prostate cancer cells, brain cells, endocrine tissue cells, bone marrow cells, lymph node cells, lung cells, gallbladder cells, liver cells, duodenal cells, small intestinal cells, pancreatic cells, kidney cells, gastrointestinal cells, bladder cells, fat cells and soft tissue cells and skin cells). In some embodiments, the cell is obtained from a subject and may undergo a limited number of passages of primary cells, so that the cell substantially maintains natural phenotypic properties. In some embodiments, the cell to which the oligonucleotide is delivered is ex vivo or in vitro (that is, it can be delivered to the cell in the culture or delivered to the organism in which the cell resides).

[0165] In some embodiments, oligonucleotides disclosed herein can be introduced using appropriate nucleic acid delivery methods, including injection of a solution containing the oligonucleotide, bombardment of particles covered by the oligonucleotide, exposure of cells or organisms to a solution containing the oligonucleotide, or electroporation of cell membranes in the presence of the oligonucleotide. Other appropriate methods of delivering the oligonucleotide to cells can be used, such as lipid-mediated carrier transport, chemical-mediated transport, and cationic liposome transfection (such as calcium phosphate), etc.

[0166] Inhibition results can be confirmed by the appropriate determination of one or more properties of the assessment cell or subject or by the biochemical technique of the molecule (e.g., RNA, protein) of the assessment indication RNA expression. In some embodiments, the degree of the expression level of the oligonucleotide provided herein reducing RNA is assessed by comparing expression level (e.g., mRNA or protein level) with appropriate control (e.g., RNA expression level in the cell or cell colony or negative control delivered by the oligonucleotide not yet delivered) to evaluate. In some embodiments, the appropriate control RNAi expression level can be a predetermined level or value, so that the control level does not need to be measured each time. Predetermined level or value can be in various forms. In some embodiments, predetermined level or value can be a single cutoff value, such as median or mean.

[0167] In some embodiments, the administration of oligonucleotides as described herein causes a reduction in RNA expression levels in cells. In some embodiments, the reduction in RNA expression levels may be reduced to 1% or less, 5% or less, 10% or less, 15% or less, 20% or less, 25% or less, 30% or less, 35% or less, 40% or less, 45% or less, 50% or less, 55% or less, 60% or less, 70% or less, 80% or less, or 90% or less compared to appropriate control RNA levels. An appropriate control level may be an RNAi expression level in a cell or cell population that has not yet been contacted with an oligonucleotide as described herein. In some embodiments, after a limited period of time, the effect of delivering an oligonucleotide to a cell according to the methods disclosed herein is assessed. For example, at least 8 hours, 12 hours, 18 hours, 24 hours after the oligonucleotide is introduced into the cell; or at least one day, two days, three days, four days, five days, six days, seven days or fourteen days, the RNA level in the cell may be analyzed.

[0168] In some embodiments, the oligonucleotide is delivered in the form of a transgenic engineered to express the oligonucleotide in a cell (e.g., its sense and antisense strands). In some embodiments, the oligonucleotide is delivered using a transgenic engineered to express any of the oligonucleotides disclosed herein. The transgene may be delivered using a viral vector (e.g., adenovirus, retrovirus, vaccinia virus, poxvirus, adeno-associated virus, or herpes simplex virus) or a non-viral vector (e.g., plasmid or synthetic mRNA). In some embodiments, the transgene may be injected directly into the subject.

[0169] (b) Treatment methods

[0170] Aspects of the present disclosure relate to methods for reducing RNA expression to alleviate the onset or progression of various diseases. In some embodiments, the present disclosure provides methods for using the RNAi oligonucleotides of the present invention for treating subjects suffering from or suspected of having liver diseases (such as cholestatic liver disease, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)). In some embodiments, the present disclosure provides RNAi oligonucleotides described herein for treating subjects suffering from or suspected of having liver diseases (such as cholestatic liver disease, NAFLD and NASH). In some embodiments, the present disclosure provides RNAi for the preparation of drugs for treating subjects suffering from or suspected of having liver diseases (such as cholestatic liver disease, NAFLD and non-alcoholic steatohepatitis NASH).

[0171] In another aspect, the present invention relates to a method for treating a subject suffering from a disease or being at risk of a disease caused by the expression of a target gene. In this embodiment, oligonucleotides can serve as novel therapeutic agents for controlling one or more of the following: cell proliferation and / or differentiation disorders, disorders associated with bone metabolism, immune disorders, hematopoietic dysfunction, cardiovascular disorders, liver disorders, viral diseases or metabolic disorders. The method includes administering a pharmaceutical composition of the present invention to a patient (e.g., a person) so that the expression of the target gene is silenced. Due to its high specificity, the oligonucleotides of the present invention specifically target the mRNA of the target gene of diseased cells and tissues.

[0172] In the prevention of disease, the target gene may be a gene required for initiation or maintenance of the disease or a gene that has been identified as being associated with a high risk of contracting the disease. In the treatment of the disease, the oligonucleotide may be contacted with cells or tissues exhibiting the disease. For example, an oligonucleotide substantially identical to all or part of a mutant gene associated with cancer or an oligonucleotide expressed at high levels in tumor cells (e.g., aurora kinase) may be contacted with or introduced into a cancer cell or tumor gene.

[0173] Examples of cell proliferation and / or differentiation disorders include cancer (e.g., carcinoma, sarcoma), metastatic disorders, or hematopoietic neoplastic disorders (e.g., leukemia). Metastatic tumors can be produced by numerous primary tumor types (including but not limited to those of prostate, colon, lung, breast, and liver origin). As used herein, the terms "cancer," "hyperproliferation," and "neoplastic" refer to cells having autonomous growth capabilities, i.e., abnormal disease states characterized by rapid proliferative cell growth. These terms are intended to include all types of cancerous growth or carcinogenic processes, metastatic tissues, or malignant transformed cells, tissues, or organs (regardless of histopathological type or invasion stage). Proliferative disorders also include hematopoietic neoplastic disorders, including diseases involving hyperplastic / neoplastic cells of hematopoietic origin, such as caused by bone marrow, lymphoid or erythroid cell lines or their precursor cells.

[0174] The present invention can also be used to treat various immune disorders, especially those associated with overexpression of genes or expression of mutant genes. Examples of hematopoietic disorders or diseases include, but are not limited to, autoimmune diseases (including, for example, diabetes, arthritis (including rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis), multiple sclerosis, encephalomyelitis, myasthenia gravis, systemic lupus erythematosus, autoimmune thyroiditis, dermatitis (including atopic dermatitis and eczematous dermatitis), psoriasis, Sjogren's Syndrome, Crohn's disease, disease), aphthous ulcers, iritis, conjunctivitis, keratoconjunctivitis, ulcerative colitis, asthma, allergic asthma, cutaneous lupus erythematosus, scleroderma, vaginitis, proctitis, drug eruption, leprosy reversal reaction, erythema nodosum leprosum, autoimmune uveitis, allergic encephalomyelitis, acute necrotizing hemorrhagic encephalopathy, idiopathic bilateral progressive sensorineural hearing loss, aplastic anemia, pure red cell anemia, idiopathic thrombocytopenia, polychondritis, Wegener's granulomatosis, chronic active hepatitis, Stevens-Johnson syndrome, idiopathic sprue, lichen planus, Graves' disease, sarcoidosis, primary biliary cirrhosis, posterior uveitis and pulmonary fibrosis), graft-versus-host disease, transplant cases, and allergies.

[0175] In another embodiment, the present invention relates to a method for treating viral diseases, including but not limited to human papillomavirus, hepatitis C, hepatitis B, herpes simplex virus (HSV), HIV-AIDS, poliovirus and smallpox virus. The oligonucleotides of the present invention are prepared as described herein to target the expressed sequences of the virus, thereby reducing viral activity and replication. The molecules can be used to treat and / or diagnose virally infected tissues of both animals and plants. In addition, such molecules can be used to treat virus-related carcinomas, such as hepatocellular carcinoma.

[0176] The oligonucleotides of the present invention can also be used to inhibit the expression of the multidrug resistance 1 gene ("MDR1"). "Multidrug resistance (MDR)" refers broadly to a pattern of resistance to various chemotherapeutic drugs with unrelated chemical structures and different mechanisms of action. Although the etiology of MDR is multifactorial, the overexpression of P-glycoprotein (Pgp), a membrane protein that mediates the transport of MDR drugs, is still the most common potential change of MDR in laboratory models (Childs and Ling, 1994). In addition, in human cancers, especially in leukemia, lymphoma, multiple myeloma, neuroblastoma and soft tissue sarcoma, Pgp expression is related to the progression of MDR (Fan et al.). Recent studies have shown that tumor cells expressing MDR-associated proteins (MRP) (Cole et al., 1992), lung resistance proteins (LRP) (Scheffer et al., 1995) and mutations of DNA topoisomerase II (Beck, 1989) can also present MDR.

[0177] In some embodiments, the target gene may be a target gene from any mammal (such as a human target). Any gene may be silenced according to the methods described herein. Exemplary target genes include, but are not limited to, factor VII, Eg5, PCSK9, TPX2, apoB, LDHA, SAA, TTR, HBV, HCV, RSV, PDGFβ gene, Erb-B gene, Src gene, CRK gene, GRB2 gene, RAS gene, MEKK gene, JNK gene, HMGB1 gene, RAF gene, Erkl / 2 gene, PCNA (p21) gene, MYB gene, JUN gene, FOS gene, BCL-2 gene, cell cycle protein D gene, VEGF gene, EGFR gene, cyclin A gene, cyclin E gene, WNT-1 gene, β-catenin gene, c-MET gene, PKC gene, NFKB gene, STAT3 gene, survivin gene, Her2 / Neu gene, topoisomerase I gene, topoisomerase IIα gene, p73 gene, p21 (WAF1 / CIPl) gene, p27 (KIPl) gene, PPM1D gene, HAO1 gene, RAS gene, caveolin I gene, MIB I gene, MTAI gene, M68 gene, mutations in tumor suppressor genes, p53 tumor suppressor gene, LDHA, HMGB1, HAO1 and combinations thereof.

[0178] The methods described herein generally involve administering to a subject an effective amount of an oligonucleotide, i.e., an amount capable of producing a desired therapeutic outcome. A therapeutically acceptable amount may be an amount capable of treating a disease or condition. The appropriate dosage for any subject will depend on certain factors, including the subject's size, body surface area, age, the particular composition to be administered, the active ingredients in the composition, the time and route of administration, general health, and other drugs to be administered simultaneously.

[0179] In some embodiments, the subject is administered any of the compositions disclosed herein enterally (e.g., orally, using a gastric feeding tube, using a duodenal feeding tube, via gastrostomy, or rectally), parenterally (e.g., subcutaneous injection, intravenous injection or infusion, intraarterial injection or infusion, intraosseous infusion, intramuscular injection, intracerebral injection, intracerebroventricular injection, intrathecal), topically (e.g., epidermis, inhalation, via eye drops, or via a mucosa), or by direct injection into a target organ (e.g., the subject's liver). Typically, the oligonucleotides disclosed herein are administered intravenously or subcutaneously.

[0180] As a non-limiting example set, the oligonucleotides of the present invention will generally be administered quarterly (once every three months), bimonthly (once every two months), monthly or weekly. For example, the oligonucleotides may be administered weekly or every two or three weeks. The oligonucleotides may be administered daily.

[0181] In some embodiments, the subject to be treated is a human or non-human primate or other mammalian subject.Other exemplary subjects include domestic animals such as dogs and cats; livestock such as horses, cattle, pigs, sheep, goats and chickens; and animals such as mice, rats, guinea pigs and hamsters.

[0182] Example

[0183] In order to more fully understand the invention described herein, the following examples are set forth.The examples described in this application are provided to illustrate the methods, compositions and systems provided herein and should not be construed as limiting the scope thereof in any way.

[0184] Example 1: Analysis of the sense strand by replacing 2'-F with 2'-OMe at positions 17 and 19

[0185] Double-stranded RNA (dsRNA) targeting HAO1 was selected for structure activity relationship (SAR) analysis. The dsRNA comprises four rings, wherein each base is conjugated to a monosaccharide, N-acetylgalactosamine (GalNAc). The sense strand and antisense strand of the dsRNA are modified with 2'-F at positions 8 to 11 and positions 2 and 14, respectively. Compared with dsRNA modified with 2'-OMe at the same position, these modifications increase RNAi efficacy. Therefore, the 2'-F modification just mentioned remains constant during the SAR described in this article.

[0186] To test the effect of replacing 2'-F with 2'-OMe, a series of dsRNAs were constructed as shown in Table 1. To analyze the efficacy of the dsRNAs, HAO1 mRNA knockdown was measured 48 hours after transfection of different concentrations of dsRNA in the HAO1 stable cell line. The efficacy was then calculated as the half maximal inhibitory concentration (IC 50 ).like Figures 1A to 1C As shown in , similar potency was determined for each of the tested dsRNAs. Taken together, these results demonstrate that 2'-OMe modification is well tolerated on the sense strand of dsRNA.

[0187] Table 1. Sense strand structure activity relationship (SAR).

[0188]

[0189] Example 2: Analysis of the antisense strand by replacing 2'-F at positions 15, 17 and 19 with 2'-OMe.

[0190] As shown in Table 2, the antisense strand was studied by replacing 2'-F with 2'-OMe at positions 15, 17, and 19 on the antisense strand. The modifications of the sense strand of the dsRNA were kept constant in this analysis (Table 2). FIG. 2A to FIG. 2D As shown in , similar potency was determined for each of the dsRNAs tested. Taken together, these results demonstrate that 2'-OMe modifications are well tolerated at positions 15, 17, and 19 of the antisense strand of dsRNA.

[0191] Table 2. Antisense SAR (#1).

[0192]

[0193] Example 3: Analysis of the antisense strand by replacing 2'-F with 2'-OMe at positions 1 to 10.

[0194] As shown in Table 3, the antisense strand was investigated by replacing 2'-F with 2'-OMe at positions 1 to 10 on the antisense strand (also referred to as the seed region), such as 3A to 3H As shown in , 2'-OMe modifications at positions 7 and 9 were well tolerated. However, when 2'-F modifications at positions 2 and 5 and other positions in the seed region were replaced by 2-OMe, as shown by IC 50 The RNAi efficacy measured by the value was reduced ( Figures 3A to 3G ). Taken together, the results demonstrate that 2'-OMe is poorly tolerated in the seed region of the antisense strand and that position 5 is preferentially modified with 2'-F over 2'-OMe.

[0195] Table 3. Antisense strand SAR (#2).

[0196]

[0197] Example 4: Analysis of the antisense strand by replacing 2'-F at positions 1, 6, 8, 10 and 15 with 2'-OMe.

[0198] As shown in Table 4, the antisense strand was investigated by replacing 2'-F with 2'-OMe at positions 1, 6, 8, 10, and 15 on the antisense strand. FIG. 4A to FIG. 4E As shown in , the 2'-OMe modification at position 15 was well tolerated, which is consistent with the results obtained in Example 2. The effect of the 2' modification at position 1 of the antisense strand containing a phosphate mimetic at the 5' end was examined. Similar efficacy was observed between 2'-OMe and 2'-F at position 1 ( FIG. 4C to FIG. 4D ). Next, the effect of 2' modifications at positions 2 and 14 only of the antisense strand was examined and similar IC values ​​were obtained compared to the others tested. 50 value( FIG. 4A to FIG. 4E ). Taken together, the results confirm that 2'-OMe is tolerated on the antisense strand.

[0199] Table 4. Antisense SAR (#3).

[0200]

[0201] Example 5: Analysis of the antisense strand by adding 2'-F at positions 3 to 6.

[0202] Next, a low 2'-F pattern (2'-F at positions 2 and 14 only of the antisense strand) was selected as the starting point, and 2'-F was gradually added to the seed region at positions 3 to 6 to probe the sensitivity in that region. As shown in Table 5, the starting molecule had the same modification pattern as the last molecule shown in Table 4, except that the molecule contained a different phosphate mimetic at antisense position 1. Based on IC 50 As a result, the 2'-F modification at position 5 showed increased potency compared to the 2'-F modifications at positions 3, 4, and 6 ( FIG. 5A to FIG. 5H ). These results further confirm that in some low 2'-F patterns, position 5 may prefer 2'-F over 2'-OMe. In addition, when 2'-F at position 5 was tested in combination with 2'-F at other positions (such as 2'-F at position 3 or position 6), increased potency was observed ( FIG. 5A to FIG. 5H ).

[0203] Table 5. Antisense strand SAR seed region (circle 2 - positions 3 to 6).

[0204]

[0205] Example 6: Analysis of the antisense strand by replacing 2'-F at positions 7 to 10 with 2'-OMe and maintaining 2'-F at positions 3 and 5.

[0206] Next, positions 7 to 10 on the antisense strand were investigated (Table 6). In this analysis, 2'-F modifications were maintained at positions 5 and 3, and a phosphate mimetic with a 2'-F modification was maintained at position 1. Fig. 6A As shown in Figure 2, control 1 exhibited excellent IC after 66 hours of transfection in the HAO1 stable cell line. 50 (3.5 pM). To probe the effect of 2'-F on positions 7 to 10, 2'-OMe was added to position 9 of the sense strand. 50 This modification will provide a wider dynamic range. As shown in Figure 6, the IC 50 >10 times higher than control 1 ( FIG. 6A to FIG. 6B When 2'-F was substituted at positions 7 to 10, an increase in potency was observed ( 6A to 6F ). The results showed that modification with 2'-F at position 7 or position 10 improved the efficacy, but modification with 2'-F at position 8 or position 9 did not improve the efficacy.

[0207] Table 6. Antisense strand SAR (circle 2 - positions 7 to 10).

[0208]

[0209]

[0210] Example 7: Minimal 2'-F Set for In Vivo Studies of HAO1

[0211] In summary, the efficacy experimental results demonstrated herein confirm that the antisense strand is more sensitive to 2'-OMe modification than the sense strand. Positions on the antisense strand that prefer 2'-F over 2'-OMe were identified, including positions 2, 3, 5, 7, 10, and 14. Among positions 3, 5, 7, and 10, position 5 is more obvious in its preference for 2'-F over 2'-OMe. The modification patterns at the positions just mentioned can provide opportunities to balance efficacy, duration, and tolerance. The experimental results also show that the sense strand can tolerate more 2'-OMe modifications than the antisense strand. In addition, positions 8 to 11 on the sense strand prefer 2'-F over 2'-OMe, but 2'-OMe insertions in this region are tolerant, especially when combined with the best modification on the antisense strand.

[0212] To test the in vivo activity of HAO1 conjugates containing minimal 2'-F and heavy 2'-OMe modification patterns, HAO1 conjugates were administered to mice and target knockdown was assessed. The HAO1 conjugates tested in mice are shown in Table 7. The HAO1 conjugate containing heavy 2'-F was used as a control.

[0213] Table 7. HAO1 conjugates used for in vivo studies.

[0214]

[0215] like 7A to 7H As shown in Figure 2, HAO1 conjugates containing minimal 2'-F and heavy 2'-OMe modification patterns exhibited excellent in vitro potency (IC 50 ), and its IC 50 The HAO1 conjugates shown in Table 7 were also administered to mice by subcutaneous injection of a single dose of 1 mpk. Hepatic HAO1 mRNA expression was measured relative to the PBS control group 3 days after dosing. Fig.7IAs shown in, HAO1 conjugates containing minimal 2'-F and heavy 2'-OMe modification patterns exhibited comparable in vivo KD activities compared to those of heavy 2'-F controls. No differences were detected between 2'-F or 2'-OMe modifications in combination with phosphate mimics at position 1 of the antisense strand. No differences were observed at day 3 for a comparison of 2'-OMe and 2'-F at antisense position 1 in combination with phosphate mimics. These results confirm the correlation between the in vitro and in vivo activities of the HAO1 conjugates containing minimal 2'-F and heavy 2'-OMe modification patterns described herein.

[0216] Example 8: HAO1 Duration Study

[0217] Compared to modification with 2'-F, modification with 2'-OMe generally provides better metabolic stability towards nuclease degradation. Therefore, nucleic acids modified with minimal 2'-F and heavy 2'-OMe should last longer in cells. To test whether nucleic acids modified with 2'-OMe remain longer in cells, a duration study was performed using selected HAO1 conjugates tested in previous in vivo studies (Table 8). Figure 8 As shown in , minimal 2'-F and heavy 2'-OMe modified nucleic acids exhibited better mRNA knockdown at longer time points, and thus better duration of RNAi activity in vivo, compared to heavy 2'-F controls.

[0218] Table 8. Selected HAO1 conjugates used for HAO1 duration studies.

[0219]

[0220] Example 9: APOC3 conjugates with minimal 2'-F and heavy 2'-OMe modifications

[0221] To confirm that nucleic acids with minimal 2'-F and heavy 2'-OMe modification patterns can be applied to other target sequences, the modification patterns of the HAO1 conjugates shown in Table 7 were transferred to the APOC3 sequence. The resulting APOC3 conjugates shown in Table 9 were tested in vitro and in vivo.

[0222] Table 9. APOC3 conjugates.

[0223]

[0224] For in vitro experiments, HEK-293 cells were co-transfected with 100 ng of pcDNA3-mAPOC3 plasmid (containing cDNA of mouse APOC3) and siRNA at the specified concentration using Dharmafect Duo reagent (Dharmacon) according to the manufacturer's protocol. The next day, cells were lysed and RNA was purified using the SV96 kit (Promega). Purified RNA was reverse transcribed using a high-capacity RT kit (Life Technologies) and APOC3 cDNA was quantified with RT-qPCR using a genetic assay for mouse APOC3 standardized for human SFRS9. As shown in FIG9 , APOC3 conjugates with minimal 2'-F and heavy 2'-OMe modification patterns were well tolerated and showed similar in vitro activity compared to heavy 2'-F controls.

[0225] For in vivo experiments, CD-1 mice were divided into study groups and subcutaneously administered with 1 mg / kg of the designated APOC3 conjugates. Animals were bled via lateral tail vein puncture on day 7 after dosing with a collection volume of 10 μL. The collected whole blood was immediately diluted 1:5000 in cold PBS and then frozen at -20°C. Whole blood with a final dilution of 1:10,000 was used to determine plasma APOC3 levels using Cloud Clone Corporation ELISA (SEB890Mu). As seen in Figure 9, at day 7 after dosing, APOC3 conjugates with minimal 2'-F and heavy 2'-OMe modification patterns showed good activity, while the heavy 2'-F control did not show activity.

[0226] Example 10: GYS2 conjugates with minimal 2'-F and heavy 2'-OMe modifications

[0227] To confirm that nucleic acids with minimal 2'-F and heavy 2'-OMe modification patterns can be applied to other target sequences, the modification patterns of the HAO1 conjugates shown in Table 7 were transferred to different GYS2 sequences. The resulting GYS2 conjugates are shown in Table 10. Two minimal 2'-F patterns were selected and compared with the heavy 2'-F pattern (Table 10). For each of the three patterns, 3 phosphorothioates (3PS) or 2 phosphorothioates (2PS) were included at the 5'-end of the antisense strand. The GYS2 conjugates contain 3 GalNAc-conjugated nucleotides in the loop region. Four different GYS2 sequences containing the patterns in Table 10 were tested.

[0228] Table 10. Modification patterns of GYS2 conjugates.

[0229]

[0230] like Fig.10As shown in , minimal 2'-F and heavy 2'-OMe modification patterns 1 and 2 were well tolerated in vivo compared to heavy 2'-F controls, specifically, these patterns were tolerated 4 days after a single subcutaneous dose of 0.5 mg / kg. Similar results were obtained for each of the four GYS2 sequences tested.

[0231] In summary, several advanced tetracyclic GalXC designs with reduced 2'-F content and increased 2'-OMe content were developed, which can be applied to multiple target genes and sequences with optimal efficacy and duration.

Claims

1. An oligonucleotide comprising: A sense strand comprising 17 to 36 nucleotides, wherein the sense strand has a first region (R1) and a second region (R2), wherein the second region (R2) of the sense strand comprises a first subregion (S1), a second subregion (S2), and a tetraloop (L) or a triloop (triL) joining the first region and the second region, wherein the first subregion and the second subregion form a second duplex (D2); an antisense strand comprising 20 to 22 nucleotides, wherein the antisense strand comprises at least 1 single-stranded nucleotide at its 3' end, wherein the sugar moiety of the nucleotides at positions 2, 5 and 14 of the antisense strand is modified with 2'-F and the sugar moiety of each of the remaining nucleotides of the antisense strand is modified with a modification selected from the group consisting of: 2'-O-propargyl, 2'-O-propylamino, 2'-amino, 2'-ethyl, 2'-aminoethyl (EA), 2'-fluoro (2'-F), 2'-O-methyl (2'-OMe), 2'-O-methoxyethyl (2'-MOE), 2'-O-[2-(methylamino)-2-oxoethyl] (2'-O-NMA) and 2'-deoxy-2'-fluoro-β-d-arabinoic acid (2'-FANA), and wherein the sense strand and the antisense strand are separate strands; A first duplex (D1) formed by the first region of the sense strand and the antisense strand, wherein the first duplex is 12 to 20 base pairs in length and has 7 to 10 nucleotides modified with 2'-F at the 2'-position of the sugar moiety.

2. The oligonucleotide of claim 1, wherein the sugar moiety at each of up to 3 nucleotides at positions 1, 3, 7 and 10 of the antisense strand is additionally modified with 2'-F. 3 . The oligonucleotide of claim 1 , wherein the sugar moiety of each of the nucleotides at positions 8 to 11 of the sense strand is additionally modified with 2′-F.

4. The oligonucleotide of claim 1, wherein the sugar moiety of each of the nucleotides at positions 1 to 7 and 12 to 20 of the sense strand is modified with a modification selected from the group consisting of 2'-O-propargyl, 2'-O-propylamino, 2'-amino, 2'-ethyl, 2'-aminoethyl (EA), 2'-O-methyl (2'-OMe), 2'-O-methoxyethyl (2'-MOE), 2'-O-[2-(methylamino)-2-oxoethyl] (2'-O-NMA), and 2'-deoxy-2'-fluoro-β-d-arabinoic acid (2'-FANA).

5. The oligonucleotide of claim 1, wherein the sugar moiety of each of the nucleotides at positions 1 to 7 and 12 to 17 of the sense strand is modified with a modification selected from the group consisting of 2'-O-propargyl, 2'-O-propylamino, 2'-amino, 2'-ethyl, 2'-aminoethyl (EA), 2'-O-methyl (2'-OMe), 2'-O-methoxyethyl (2'-MOE), 2'-O-[2-(methylamino)-2-oxoethyl] (2'-O-NMA), and 2'-deoxy-2'-fluoro-β-d-arabinoic acid (2'-FANA).

6. The oligonucleotide of claim 1, wherein the sugar moiety of each of the nucleotides at positions 2, 5 and 14 of the antisense strand is modified with 2'-F and the sugar moiety of each of the remaining nucleotides of the antisense strand is modified with a modification selected from the group consisting of: 2'-O-propargyl, 2'-O-propylamino, 2'-amino, 2'-ethyl, 2'-aminoethyl (EA), 2'-O-methyl (2'-OMe), 2'-O-methoxyethyl (2'-MOE) and 2'-deoxy-2'-fluoro-β-d-arabinoic acid (2'-FANA).

7. The oligonucleotide of claim 1, wherein the sugar moiety of each of the nucleotides at positions 1, 2, 5 and 14 of the antisense strand is modified with 2'-F and the sugar moiety of each of the remaining nucleotides of the antisense strand is modified with a modification selected from the group consisting of: 2'-O-propargyl, 2'-O-propylamino, 2'-amino, 2'-ethyl, 2'-aminoethyl (EA), 2'-O-methyl (2'-OMe), 2'-O-methoxyethyl (2'-MOE) and 2'-deoxy-2'-fluoro-β-d-arabinoic acid (2'-FANA).

8. The oligonucleotide of claim 1, wherein the sugar moiety of each of the nucleotides at positions 1, 2, 3, 5, 7 and 14 of the antisense strand is modified with 2'-F and the sugar moiety of each of the remaining nucleotides of the antisense strand is modified with a modification selected from the group consisting of: 2'-O-propargyl, 2'-O-propylamino, 2'-amino, 2'-ethyl, 2'-aminoethyl (EA), 2'-O-methyl (2'-OMe), 2'-O-methoxyethyl (2'-MOE) and 2'-deoxy-2'-fluoro-β-d-arabinoic acid (2'-FANA).

9. The oligonucleotide of claim 1, wherein the sugar moiety of each of the nucleotides at positions 2, 3, 5, 7 and 14 of the antisense strand is modified with 2'-F and the sugar moiety of each of the remaining nucleotides of the antisense strand is modified with a modification selected from the group consisting of: 2'-O-propargyl, 2'-O-propylamino, 2'-amino, 2'-ethyl, 2'-aminoethyl (EA), 2'-O-methyl (2'-OMe), 2'-O-methoxyethyl (2'-MOE) and 2'-deoxy-2'-fluoro-β-d-arabinoic acid (2'-FANA).

10. The oligonucleotide of claim 1, wherein the sugar moiety of each of the nucleotides at positions 1, 2, 3, 5, 10 and 14 of the antisense strand is modified with 2'-F and the sugar moiety of each of the remaining nucleotides of the antisense strand is modified with a modification selected from the group consisting of: 2'-O-propargyl, 2'-O-propylamino, 2'-amino, 2'-ethyl, 2'-aminoethyl (EA), 2'-O-methyl (2'-OMe), 2'-O-methoxyethyl (2'-MOE) and 2'-deoxy-2'-fluoro-β-d-arabinoic acid (2'-FANA).

11. The oligonucleotide of claim 1, wherein the sugar moiety of each of the nucleotides at positions 2, 3, 5, 10 and 14 of the antisense strand is modified with 2'-F and the sugar moiety of each of the remaining nucleotides of the antisense strand is modified with a modification selected from the group consisting of: 2'-O-propargyl, 2'-O-propylamino, 2'-amino, 2'-ethyl, 2'-aminoethyl (EA), 2'-O-methyl (2'-OMe), 2'-O-methoxyethyl (2'-MOE) and 2'-deoxy-2'-fluoro-β-d-arabinoic acid (2'-FANA).

12. The oligonucleotide of claim 1, wherein the sugar moiety of each of the nucleotides at positions 2, 3, 5, 7, 10 and 14 of the antisense strand is modified with 2'-F and the sugar moiety of each of the remaining nucleotides of the antisense strand is modified with a modification selected from the group consisting of: 2'-O-propargyl, 2'-O-propylamino, 2'-amino, 2'-ethyl, 2'-aminoethyl (EA), 2'-O-methyl (2'-OMe), 2'-O-methoxyethyl (2'-MOE) and 2'-deoxy-2'-fluoro-β-d-arabinoic acid (2'-FANA).

13. The oligonucleotide of claim 1 or 12, wherein the antisense strand has 3 nucleotides modified with 2'-F at the 2'-position of the sugar moiety.

14. The oligonucleotide of any one of claims 1-12, wherein the second duplex is 1 to 6 base pairs in length.

15. The oligonucleotide of any one of claims 1-12, wherein the second duplex comprises at least one bicyclic nucleotide.

16. The oligonucleotide of claim 15, wherein the second duplex is 1 to 3 base pairs in length.

17. The oligonucleotide of any one of claims 1 to 12, wherein the triloop has a nucleotide sequence of GAA or AAA or wherein the tetraloop is an RNA tetraloop selected from the group consisting of GAAA, UNCG, GNRA or CUUG or a DNA tetraloop selected from the group consisting of d(GNAB), d(CNNG) or d(TNCG), wherein N is any one of U, A, C, G, and R is G or A.

18. The oligonucleotide of claim 1, wherein the sugar moiety of each nucleotide in the second duplex is modified with 2'-O-methyl (2'-OMe).

19. The oligonucleotide of any one of claims 1-12, wherein at least one of the nucleotides in the tetraloop or the triloop is conjugated to a ligand.

20. The oligonucleotide of claim 19, wherein 1 to 3 nucleotides in the triloop or 1 to 4 nucleotides in the tetraloop are conjugated to a ligand.

21. The oligonucleotide of claim 19, wherein the ligand comprises N-acetylgalactosamine.

22. The oligonucleotide of any one of claims 1-12, wherein the nucleotide at position 1 of the antisense strand comprises a phosphate mimetic.

23. The oligonucleotide of any one of claims 1-12, wherein the sense strand comprises 36 nucleotides and the antisense strand comprises 22 nucleotides.

24. A pharmaceutical composition comprising the oligonucleotide of any one of the preceding claims and a pharmaceutically acceptable carrier.

25. Use of the oligonucleotide of any one of claims 1 to 23 or the composition of claim 24 in the preparation of a medicament for reducing the expression of a target gene in a subject, wherein the oligonucleotide or the composition is administered to the subject in an amount sufficient to reduce the expression of the target gene in the subject.

26. Use of the oligonucleotide of any one of claims 1 to 23 or the composition of claim 24 in the preparation of a medicament for treating or preventing a disease or condition in a subject, wherein the oligonucleotide or composition is administered to the subject in an amount sufficient to inhibit the expression of a gene causing the disease in the subject.